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CHAPTER I 
 
INTRODUCTION 
 
Many organisms, such as bacteria, plants and fungi are capable of synthesizing 
structurally diverse bioactive natural products. The diversity of structure and bioactivity 
of many of these compounds led to their use in pharmaceutical and agricultural 
applications.1 Bacterial natural products often contain sugar moieties attached to their 
core scaffolds and play significant roles in conferring biological activity. Many of these 
bioactive sugars are derived from deoxyaminosugar oxidations, the most common of 
which are deoxynitrosugars.2 
The recent advances in gene cluster elucidations of several natural products 
containing these N-oxidized sugars have enabled the proposal of biosynthetic pathways 
of these important moieties and set the stage for biochemical characterization of the 
enzymes involved in their biosynthesis. The biosynthetic pathways of deoxyaminosugar 
moieties in several natural products have been well studied; however, enzymes 
responsible for the amine oxidation in many deoxynitrosugar-containing and related 
natural products have not been characterized previous to our investigations. 
Given the biological importance of deoxysugar attachments, advances in 
studying new biosynthetic pathways will provide opportunities for in vivo pathway 
engineering leading to the production of new glycoconjugates with varied biological 
activities. Particularly, the characterization of the biosynthetic gene(s) for the key 
oxidation of aminosugars, clearly present the opportunity to increase the sugar 
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structural diversity of a vast array of glycosides via in vivo or in vitro pathway 
manipulation.2-3 Additionally, discovering new biocatalysts able to perform synthetically 
difficult enantioselective amine oxidations will have significant implications in the 
development of alternative synthetic methods. 
 
Biosynthesis of N-oxygenated deoxysugars 
 
Significance of deoxysugars in natural products 
Deoxysugars are common structural appendages of many bioactive natural 
products and are commonly found attached to polyketide scaffolds. Several 
therapeutically important drugs such as the antibiotic vancomycin and the anticancer 
agent doxorubicin contain sugars attached to their aglycone cores.4-5 These sugars play 
important roles in the biological activity by participating in the interaction between the 
drug and the cellular target.  In some cases, sugars participate in the mode of action of 
many drugs as they contribute to a variety of processes, including active 
transmembrane transport, stabilization of protein folding and enzyme inhibition.4-8 
The most prevalent sugars among sugar-containing bacterial secondary 
metabolites are deoxysugars, often deoxyaminosugars, the biosyntheses of which have 
been recently reviewed.3, 9 Structures of some common deoxysugars are shown in figure 
I-1. 
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Figure I-1. Examples of some deoxysugars found linked to several natural product scaffolds 
 
Deoxygenation of these sugars proceeds via nucleotide diphosphate (NDP) 
activation of 6-deoxyhexoses, usually D-glucose. The most common NDP activation is 
performed by attaching thymidine diphosphate (TDP) at the anomeric carbon of D-
glucose-1-phosphate.3 TDP-activated sugars are the most structurally diverse class of 
nucleotide sugars found in nature. After NDP-activation, deoxygenation proceeds via a 
4-keto-6-deoxy intermediate which is shared among all known deoxysugar pathways. 
A less common but very important sugar modification, deoxyaminosugar 
oxidation to hydroxylamino-, nitroso-, and nitrosugars uniquely extends nature’s 
glycochemical diversity. Natural products containing N-oxidized deoxysugars exhibit a 
broad range of biological activities including antibacterial, antitumor, antimalarial, 
anticholesteromic, antiviral, and antidiabetic activities.2, 10-12 The oxidized congeners of 
deoxyaminosugars exist in many natural products such as everninomicin, rubradirin and 
kijanimicin.13-15 The hydroxylamino-, nitroso-, and nitrosugar variants have been isolated 
from the fermentation broth of the everninomicin producer Micromonospora 
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carbonecea var. africana. It has been shown that the antibacterial activity among these 
derivatives varied significantly.16 Modulation of biological activity through enzymatic 
deoxysugar modification could have significant impact on the development of 
therapeutically important agents derived from various natural glycoconjugates. 
Because of the biological importance of these deoxysugar moieties in various 
natural products, there has been a growing interest in developing new strategies for 
altering the deoxysugar appendages of important glycoconjugates either by synthetic or 
biosynthetic engineering approaches.  Biosynthetic engineering strategies require good 
understanding of the enzymes involved in the deoxysugar modifications and attachment 
to their corresponding aglycones. The gene clusters of many bioactive compounds 
containing deoxysugars have been sequenced and deposited into gene data banks, 
which made functional assignments of the encoded enzymes feasible. This enabled 
genetic and biochemical characterization of the biosynthetic pathways of several known 
deoxysugars.  Interestingly, studying these pathways showed that several sugar 
biosynthetic enzymes and glycosyltransferases (GTs), have broad substrate specificity 
allowing their use both in vivo and in vitro for altering the sugar moieties in these 
compounds, a process termed glycodiversification. Several successful 
glycodiversification studies have been performed on natural product glycoconjugates 
such as vancomycin and calicheamicin, yielding a new generation of glycorandomized 
derivatives of altered biological activities.2, 17-18 
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These glycodiversification startegies can be applied for many other natural-
product scaffolds utilizing substrate-flexible enzymes to generate libraries of substances 
for in vitro or in vivo glycoslation. Enzymes in the deoxysugar pathways can be further 
manipulated through protein engineering which can result in an expanded pool of 
glycorandomized derivatives. This new generation of compounds of varied biological 
activities could lead to the discovery of potentially important drugs to mitigate the 
daunting threats of human diseases. 
 
Nitrosugar-containing natural products 
Deoxynitrosugars are found in many isolated secondary metabolites with diverse 
scaffolds including spirotetronate antibiotics, ansamycins, and orthosomycins.13-15 One 
of the first reported deoxynitrosugar-containing natural products is the orthosomycin 
antibiotic everninomicin from Micromonospora carbonacea var. africana which includes 
a deoxynitrosugar moiety, evernitrose.15  This nitrosugar is called D-rubranitrose in the 
polyketide rubradirin isolated from Streptomyces achromogenes and is structurally 
related to D-kijanose from the spirotetronate polyketide antibiotic kijanimycin produced 
by the Actinomycete Actinomadura kijaniata.14, 19  These compounds possess potent 
antibacterial activity among other important biological activities. Below is a brief 
description of these three important nitrosugar-containing natural products with 
emphasis on the significance of their attached nitrosugar moiety. 
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Everninomicin 
Everninomicin, producd by Micromonospora  carbonacea var. africana, is an 
oligosaccharide which belongs to the orthosomycin class of antibiotics and possesses 
potent activity against Gram-positive and Gram-negative bacteria including vancomycin 
resistant enterococci, methicillin resistant staphylococci, and penicillin-resistant 
streptococci.20 The structure of everninomicin is composed of eight deoxysugars 
including a terminal nitrosugar (L-evernitrose), and acelytated with orsellinic and 
dichloroisoeverninic acid moieties (Figure I-2). 
 
 
Figure I-2. Chemical structure of everninomicin. 
 
The mechanism of action of everninomicin involves inhibition of protein 
biosynthesis by binding to the ribosomal protein L16 which affects the function of the 
50S ribosomal subunit.21 Everninomicin was developed through phase III clinical studies 
when its further development was discontinued in May of 2000 for the stated reason: 
“the balance between efficacy and safety did not justify further development of the 
product”.22 However, because of its potent antibacterial activity, researchers have been 
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interested in its structure diversification to create a number of everninomicin 
derivatives for structure-activity studies. Only limited chemical derivatization 
experiments of everninomicin were performed for that purpose, which proved 
challenging perhaps because of the complexity of the sugar linkages in orthosomycins.23 
This gave rise to the interest of studying the biosynthesis of everninomicin which could 
potentially lead to the utilization of the natural biocatalysts in its biosynthetic pathway 
to compliment the chemical synthetic methods in the rational drug design process. 
The deoxynitrosugar moiety in everninomicin was shown to be important for the 
antibacterial activity. For instance, antibacterial activity of the nitrosugar congener 
against Staphylococcus aureus was shown to be 125 fold higher compared to  that of the 
amino-sugar congener.16 This highlights the significance of studying the enzymes 
responsible for the N-oxidation of this important deoxysugar moiety. The knowledge 
that can be gained from understanding this important biochemical transformation could 
greatly impact current efforts towards everninomicin structure diversification. 
 
Rubradirin 
Rubradirin, produced by Streptomyces achromogenes var. rubradiris, is an 
ansamycin antibiotic that possesses significant activity against Gram-positive bacteria 
including multidrug-resistance strains of Staphylococcus aureus.19 The structure of 
rubradirin is comprised of four distinct moieties; the polyketide scaffold rubransarol, 3-
amino-4-hydroxy-7-methoxycoumarin (AMC), the aromatic bridge 3,4-
 
 
8 
 
dihydroxydipicolinate (DHDP), and the nitrosugar D-rubranitrose (2,3,6-trideoxy-3-C-4-O-
dimethyl- 3-C-nitro-D-xylo-hexose), (Figure I-3). 
 
 
Figure I-3. Chemical structure of rubradirin. 
 
The antibacterial activity of rubradirin involves inhibition of the function of 
microbial ribosomes by selective prevention of translation chain initiation during protein 
synthesis. 24 It has also been shown that the aglycone of rubradirin is a potent inhibitor 
of the human immunodeficiency virus (HIV) reverse transcriptase.25 The polyketide 
scaffold rubransarol does not inhibit bacterial RNA polymerase or ribosomal functions 
on its own, which highlights the importance of the additional structural elements in 
rubradirin including the deoxynitrosugar moiety. 
The gene cluster of rubradirin has been recently sequenced and deposited in the 
NCBI gene data bank. Functional analysis of this cluster based on sequence homologies, 
identified the genes responsible for the biosynthesis of the aminosugar precursor of the 
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nitrosugar D-rubranitrose.13 The lack of a gene that encodes a C-5 epimerase in the 
rubradirin gene cluster is consistent with the D-configuration of the nitrosugar moiety.  
Additionally, a putative oxidase gene, rubN8, was also found in the rubradirin gene 
cluster and proposed to perform N-oxidation of an aminosugar precursor in the 
biosynthesis of D-rubranitrose. 
It is worth noting that only the nitroso congener of rubradrin (protorubradirin) 
was isolated from the fermentation of the producer Streptomyces achromogenes var. 
rubradiris when it was grown in complete darkness. After isolation, protorubradirin 
readily converted to rubradin upon exposure to ambient light.  Based on this 
observation, it was proposed that the nitroso congener of rubradirin is the true 
secondary metabolite and that the nitro group is formed through photooxidation.26 
 
Kijanimicin 
Kijanimicin, produced by Actinomadura kijaniata, is a spirotetronate antibiotic 
and exhibits a broad range of antibacterial activity against Gram-positive bacteria, 
anaerobes, and the malaria parasite Plasmodium falciparum.14 It has also been shown 
that derivatives of kijanimicin possess potent activity against human liver and breast 
cancer cell lines.27 The structure of kijanimicin includes a pentacyclic polyketide core, 
linked to four L-digitoxose units and the nitrosugar, 2,3,4,6-tetradeoxy-4-
(methylcarbamyl)-3-C-methyl-3-nitro-D-xylo hexopyranose known as D-kijanose (Figure I-
4). Kijanimicin derivatives are also known to be produced by other high-GC Gram-
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positive bacterial strains (actinomycetes) such as Streptomyces, Micromonospora, 
Actinomadura, Saccharothrix, and Verrucosispora.14 Most members of this class of 
compounds exhibit antibacterial and antitumor activities and many possess other 
biological activities. Examples of these compounds include tetrocarcins and arisostatins, 
which have been shown to be inducers of apoptosis;28 chlorothricins, as 
anticholesterolemic agents;29 tetronothiodin, a cholecystokinin B (CCK-B) inhibitor;30 
MM46115, an antiviral drug active against parainfluenzae virus 1 and virus 2.31 
 
 
Figure I-4. Chemical structure of kijanimicin. 
 
The deoxysugar moieties that decorate the polyketide core of kijanimicin play an 
important role in the biological activity of this compound. Although no structure-activity 
studies yet assed the importance of the D-kijanose sugar, it is likely that this unusually 
modified deoxynitrosugar is important for biological activity. 
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Biosynthesis of deoxyaminosugars 
Deoxyaminosuagrs are an important class of deoxysugar moieties biosynthesized 
by a variety of organisms such as plants, fungi and bacteria.32 Based on gene functional 
analysis of several natural products possessing N-oxidized deoxysugars, it is largely 
thought that the precursors of these important moieties are deoxyaminosugars. 
Therefore, understanding the biosynthetic pathways of these sugar precursors is very 
helpful in the elucidation of the N-oxidation pathway. Before the introduction of the 
amine group, the precursor sugar must be in its deoxygenated form. Enzymatic 
deoxysugar modifications are always carried out on nucleotide activated sugars such as 
thymidine diphosphate (TDP)-sugars. All known TDP-sugars are derived from glucose-1-
phosphate which is converted to TDP-glucose by a thymidilyl transferase and then to 
TDP-4-keto-6-deoxy-D-glucose by TDP-D-glucose 4,6-dehydratase (Scheme I-1). This 
provides the entry point for further deoxygenation and other enzymatic modification 
steps including transamination.3 
 
 
Scheme  I-1. Entry point into TDP-deoxysugar secondary metabolism in bacteria. 
 
Deoxyaminosugars are produced from their deoxygenated ketosugar precursors 
via a transamination reaction carried out by a transaminase or an aminotransferase 
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which substitutes the keto group with an amino group. These enzymes are usually 
dependent on pyridoxal phosphate (PLP), a cofactor that reacts with glutamate, which 
transfers its α-amino group to PLP to make pyridoxamine phosphate (PMP). PMP then 
transfers its nitrogen to the sugar, forming an aminosugar.33 Aminotransferase catalysis 
proceeds via a highly conserved mechanism typically yielding regio- and 
enantioselective amine installation.34 
The structure of DesI, an aminotransferase involved in D-desosamine 
biosynthesis in Streptomyces venezuelae,  in the presence of PLP and the aminosugar 
product revealed an external aldimine intermediate in which a lysine residue is in close 
proximity to both C-4’ of PLP and the C-4 atom of the sugar substrate.35  This residue 
likely plays a role in mediating the proton transfers that occurs during the 
transamination yielding a C-4 equatorial amine installation.  Unlike DesI, PseC another C-
4 aminotransferase from Helicobacter pylori, introduces a C-4 axial amino group into a 
4-ketosugar.36 Interestingly, the hexose moiety was found to be rotated by 180° in PseC 
compared to DesI resulting in this interesting opposite stereochemistry of the amino 
group. 
 
Biosynthesis of TDP-L-epi-vancosamine 
The biosynthesis of TDP-L-epivancosamine (Scheme I-2) is a good example to 
discuss because this unusual moiety is one of the most modified deoxyaminosgurs 
found in natural products. Eight enzymatic steps are required for its biosynthesis 
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starting from glucose. There are two L-epivancosamine sugars linked to the aglycone 
scaffold in chloroeremomycin, a member of the vancomycin family of glycopeptide 
antibiotics produced by Amycolatopsis orientalis.37 The biosynthetic gene cluster of 
chloroeremomycin has been sequenced which facilitated the in vitro studies of TDP-L-
epivancosamine bisosynthesis.38  In these studies, five enzymes from the 
chloroeremomycin pathway, EvaA-E, have been shown to be involved in its biosynthesis 
starting from TDP-6-deoxy-4-keto-D-glucose.39 These five enzymes were shown to 
perform C-2 deoxygenation by EvaA, C-3 amination and methylation by EvaB and EvaC 
respectively, C-5 epimerization by EvaD, and C-4 ketoreduction by EvaE (Scheme I-2). 
To reconstitute the biosynthesis of TDP-L-epivancosamine in vitro, the TDP-
glucose 4,6-dehydratse (RfbB) from the rhamnose biosynthetic pathway, was used to 
generate the entry sugar TDP-4-keto-6-deoxy-α-D-glucose.40 The RfbB activity requires 
nicotinamide adenine dinucleotide phosphate (NADP+) which is bound to the enzyme. It 
was shown that the dehydration by EvaA, 2,3-dehydratase, produces the unstable TDP-
linked 3,4-dioxo-6-deoxy sugar which is susceptible to TDP elimination with 1,2-olefin 
formation.39 The 3-amino group is formed upon the activity of the aminotransferase, 
EvaB, a PLP dependent enzyme. It was also shown that the activity of this enzyme is 
enhanced by the inclusion of 1 mM glutamine in the assay. The C-3 methylation step is 
carried out by the activity of EvaC, a SAM dependent methyltransferase. This 
methylation is followed by the activity of the C-5 epimerase EvaD which results in a 
change of the sugar configuration from D to L. The final step of TDP-L-epivancosamine 
biosynthesis is the activity of the NADPH-dependent C-4 ketoreductase, EvaE, which 
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reduces the keto group on C-4 to a hydroxyl group. TDP-L-epivancosamine is then 
attached to the aglycone scaffold of chloroeromomycin by a glycosyltransferase. 
 
 
 Scheme I-2. Biosynthesis of TDP-L-epi-vancosamine. 
 
Comparative genomics of the nitro sugar functionality 
The availability of gene cluster data of many isolated natural products provided 
the opportunity to analyze genes based on sequence and propose functions prior to 
carrying out biochemical characterization of the encoded enzymes. Sequence based 
analysis alone is insufficient for identifying/discovering a precise biosynthetic gene 
especially for large gene clusters that may contain up to 100 genes. However, multiple 
gene clusters of related compounds can be analyzed via a comparative genomic 
approach which can substantially simplify identifying genes of interest. Comparative 
genomic analysis41 was performed on the related orthosomycins everninomicin and 
avilamycin which is described below.42 
 
 
15 
 
Avilamicin is another orothosomycin oligosaccharide structurally very similar to 
everninomicin but lacks the nitrosugar moiety (Figure I-5).43 It is produced by 
Streptomyces viridochromogenes and consists of heptasaccharide deoxysugar chain and 
one PKS-derived dichloroisoeveninic acid moiety. Another structural difference between 
the two oligosaccharides is the presence of the orsellenic acid moiety at C5 of the 
deoxysugar ring H of everninomicin which is replaced by an acetyl group in avilamycin. 
Like everninomicin, avilamycin was shown to be active against many Gram-
positive bacteria, including emerging problem organisms, such as vancomycin-resistant 
enterococci, methicillin-resistant staphylococci, and penicillin-resistant pneumococci. 
The mode of action of avilamycin is similar to that of everninomicin, which involves 
inhibition of protein biosynthesis by binding to the 50S ribosomal subunit of the 
bacterial ribosomes.44 
 
 
 Figure I-5: Chemical structures of everninomicin and avilamycin. 
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There are two gene clusters described for avilamicin in the public domain (AVIL, 
AVIA) and two for everninomicin (EVER, EVEA) representing four different producers. By 
comparing these four clusters and applying simple subtractive analysis, genes that are 
likely to be involved in the nitrosugar biosynthesis could be proposed. This approach led 
to the identification of nine candidate genes for the nitrosugar biosynthesis present in 
the two everninomicin producers; Micromonospora carbonacae var. aurantiaca and 
Micromonospora carbonacea var. africana, while absent in the two avilamycin 
producers; Streptomyces viridochromogenes and Streptomyces mobaraensis (Table I-
1).45 
 
Table I-1. Possible biosynthetic genes for L-evernitrose.  Nine genes present in the everninomicin gene 
clusters (EVEA and EVER) but absent in the avilamycin gene clusters (AVIL, AVIA). Orf36/42 gene pair 
(shown in red) from EVEA, EVER clusters, respectively, is the likely N-oxidase in the biosynthesis of the 
nitrosugar moiety. 
EVEA genes EVER genes Putative encoded enzymes 
Orf37 Orf43 (C3 aminotransferase) 
Orf40 Orf46 (C4 ketoreductase) 
Orf39 Orf45 (C5 epimerase) 
Orf38 Orf44 (C3 methytransferase) 
Orf35 Orf21 (glycosyltransferase) 
Orf36 Orf42 (flavin-dependent oxidase) 
Orf19 Orf4 (copper-dependent oxidase) 
Orf18 Orf3 (RNA methyltransferase) 
Orf41 Orf47 (C4 O-methlytransferase) 
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Sequence homology analysis of these genes, allowed the identification of five 
encoded enzymes involved in the biosynthesis of the aminosugar precursor that shared 
high sequence similarity and identity with their counterparts in the well characterized 
TDP-L-epivancosamine’s biosynthetic pathway.39 The nitrosugar L-evernitrose is 
structurally very similar to TDP-L-epivancosamine with the difference being the N-
oxidation on C-3 and the C4 O-methylation in L-evernitrose. Among the genes shared 
between the two pathways were genes that encode a C-3-aminotransferase, C-3 
methyltransferase, C-5-epimerase and C-4-ketoreductase. The orf35/21 gene pair was 
found to share sequence homology with genes encoding glycosyltransferases and hence 
is possibly responsible for the glycoslation of L-evernitrose. The orf41/47 gene pair 
shares sequence homology with C4 O-methyltransferases likely responsible for 
introducing the methoxy group at C4 of the nitrosugar, a functionality that is replaced 
with a hydroxyl in TDP-L-epivancosamine.  The sequence homology analyses excluded 
two of these nine genes as candidates for the biosynthesis of evernitrose. Namely, the 
orf18/3 gene pair which has reasonable homology to RNA-methyltransferase genes and 
the Orf19/4 gene pair homologous to copper-dependent oxidase genes involved in 
primary metabolism. The only remaining and likely oxidase responsible for the oxidation 
of the aminosugar among these nine gene pairs is orf36/42. The encoded proteins of 
these genes have moderate sequence homology with the flavin dependent 
monooxygenase dibenzothiophene oxidase DszC which has been shown to oxidize a 
sulfide group to a sulfone via a sulfoxide intermediate.46 ORF36 also shares moderate 
sequence similarity (~ 25%) with the acyl-CoA dehydrogenase family of enzymes. Acyl-
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CoA dehydrogenases are flavin-dependent enzymes and are used as a structural model 
for class-D flavin-dependent monooxygenases. 
 
Proposed deoxysugar N-oxidation pathway 
As mentioned above, the oxidase proposed to form the nitrosugar congener 
from the deoxyaminosugar precursor in the everninomicin pathway is ORF36 from 
Micromonospora carbonacea var. africana. This putative flavin-dependent enzyme 
shares high sequence identity and similarity with other homologues in the biosynthetic 
pathways of nitrosugar-containing natural products such as RubN8 from the rubradirin 
pathway and KijD3 from the kijanimicin pathway.  All of these putative N-oxidases share 
moderate homology with the flavin-dependent dibenzothiophene oxidase DszC which 
oxidizes dibenzothiophene (DBT) to DBT sulfone (DBTO2) as shown in scheme I-3. This 
two-step oxidation requires the flavin mononucleotide (FMN) and the NADPH cofactors 
as well as an external flavin reductase to provide reduced flavin which mediates the 
monooxygenation catalysis. Reduced flavin is known to react with molecular oxygen to 
form the C4a-hydroperoxyflavin, a reactive oxygen species that is responsible for the 
electrophilic oxidation of the substrate.47 The oxygenation step results in the 
incorporation of one oxygen atom into the substrate, usually as a hydroxyl group, and 
the formation of the C4a-hydroxyflavin. The hydroxyflavin readily loses a water 
molecule and is recycled to participate in further rounds of oxidations. 
 
 
 
19 
 
 
Schem I-3. Oxidation of dibenzothiophene by DszC. 
 
The oxidation mechanism for the aminosugars by the putative flavin-dependent 
oxidases could be envisioned in a similar manner whereby the reduced flavin is provided 
by the function of an external flavin reductase. Monooxygenation mediated by C4a-
hydroperoxyflavin results in the formation of a hydroxylamine intermediate and 
consequently, similar flavin-dependent oxidation steps result in the production of 
further oxidized intermediates perhaps via the nitroso and ultimately the nitro 
functionality. 
 
Anthracyclines and deoxyaminosugar oxidation 
 
A brief history of anthracycline drugs 
Anthracyclines are another class of natural products with deoxysugar moieties 
attached to their tetracyclic polyketide cores. Some anthracycline compounds are 
considered the most effective anticancer drugs and possess a wide range of activity 
against several types of human cancers.48-50 The first discovered anthracyclines were 
doxorubicin and daunorubicin when they were isolated from Streptomyces peucetius in 
early 1960s.5, 51 The tetracyclic structure of doxorubicin and daunorubicin includes 
quinone-hydroquinone groups represented by rings C-B (Figure I-6). The sugar moiety in 
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these two compounds is 3-amino-2,3,6-trideoxy-L-fucose, also known as daunosamine. 
Doxorubicin and daunorubicin share the same tetracyclic core with the difference of a 
hydroxyl group on C-13 in doxorubicin. This small structural difference has significant 
effect on the spectrum of the anticancer activity of doxorubicin vs. daunarubicin. For 
example doxorubicin and some of its analogs were found to have less acute toxicity, 
cause less cardiomyopathy, and in general more potent anticancer activity.52 
Additionally, daunorubicin shows activity in acute lymphoblastic or myeloblastic 
leukemias53 whereas doxorubicin is more active against breast cancer, childhood solid 
tumors, soft tissue sarcomas, and aggressive lymphomas.54 
 
 
Figure I-6. Chemical structure of some anthracyclines. 
 
The use of doxorubicin and daunorubicin in clinic is facing some challenges such 
as the development of resistance in tumor cells or toxicity in healthy tissues, resulting in 
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some cases in chronic cardiomyopathy and congestive heart failure (CHF) among other 
side effects. Therefore, there is a need for improved anthracycline analogs with varied 
pharmacokinetics for the treatment of different types of cancer. Hundreds of new 
doxorubicin and daunorubicin analogs were synthesized but only few of them made it to 
clinical development and approval.52 Among the best approved analogues were 
epirubicin55-58 and idarubicin59-61, alternatives to doxorubicin and daunorubicin, 
respectively. The only difference between epirubicin and doxorubicin is the 
epimerization at C-4’ of daunosamine changing the orientation of the hydroxyl from the 
axial in doxorubicin to the equatorial in epirubicin. Interestingly, this minor structural 
difference resulted in significant changes in the pharmacokinetic properties which led to 
improvements in distribution volume and total body clearance.53 The idarubicin 
analogue of daunorubicin is made from the removal of the 4-methoxy group in ring-D 
and was shown to possess broader spectrum of anticancer activity. It was speculated 
that this improved activity may be attributed to increased lipophilicty and stabilization 
of the drug-topoisomerase-DNA ternary complex.62 Other approved anthracyclin 
analogues include pirarubicin, aclacinomycin A (aclarubicin), 63-64 and mitoxantrone65-67 
(a substituted aglyconic anthraquinone). 
 
Biosynthesis of baumycin 
Baumycin is an another anthracycline compound derived from daunorubicin and 
has been shown to exhibit high efficacy against gram-positive bacteria and certain 
cancer cell lines such as leukemia cells (L1210). The structure of baumycin includes a 
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non-sugar acetal moiety attached at C-4’ position of the daunosamine sugar (Figure I-
6).68-71 
In Streptomyces peucetius, the polyketide core in baumycin is produced by a 
Type II polyketide synthase (PKS). The first 3-carbons of the 21-carbon decaketide chain 
are synthesized from the incorporation of a single propinyl starter unit from propinyl-
CoA followed be 9 iterative condensations of malonyl extender units.72 The minimal PKS 
proteins that catalyze the formation of this long chain polyketide are an acyl carrier 
protein (ACP), ketosynthase (KS) and a malonyl-CoA:ACP acyltransferase (MAT).73 The 
polyketide chain is converted to 12-deoxyalkalonic acid catalyzed by the dps gene 
cluster which includes DpsE, an NADPH dependent 9-ketoreductase, and cyclases DpsF 
and DpsY that catalyze the formation of ring D and C, respectively. The subsequent 
polyketide modifications are catalyzed by the dnr gene cluster which includes C-12 
oxygenase, a SAM dependent alkalonic acid methyltransferase, ring A cyclase, C-7 
ketoreductase, and a C-11 hydroxylase.74 This series of polyketide modifications yields ɛ- 
rhodomycinone (Figure I-6), the precursor for doxorubicin and daunorubicin. The 
daunosamine sugar is then attached by DnrS, a glycosyltransferase followed by 
additional modifications on the tetracyclic core to yield daunorubicin75, which is a 
precursor for doxorubicin and baumycin. The biosynthesis of the actal moiety at C-4’ 
position of the daunosamine sugar is unclear; however, based on gene cluster analysis; 
a possible pathway is proposed and discussed below. 
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Deoxysugar genes in anthracyclines 
The biosynthetic genes of the deoxysugar L-danosamine in doxorubicin, 
daunorubicin and baumycin were assigned based on sequence homologies with other 
sugar modifying enzymes and further studied by gene manipulation. It was shown that 
the minimal enzymes required for L-daunosamine biosynthesis and attachment are 
encoded by the dnmLMJVUTS genes.76 These genes were cloned into the heterologous 
host Streptomyces lividans and the resultant recombinant strain was fed with the 
aglycone ɛ-rhodomycinone. Scheme I-4 illustrates the enzymatic steps required for the 
biosynthesis of TDP-L-daunosamine starting from D-glucose-1-phosphate. The DnmL 
enzyme is highly homologous to the well-known glucose-1-phosphate 
thymidylyltransferases which catalyze the conversion of D-glucose-1-phosphate into 
TDP-D-glucose.77 This sugar is converted to TDP-6-deoxy-4-keto-D-glucose catalyzed by 
DnmM, a TDP-D-glucose 4,6-dehydratase. The 4-keto sugar is then further dehydrated 
by DnmT, a 2,3-dehydratase to yield the 3,4-dioxo-6-deoxysugar nucleotide which can 
be transaminated by DnmJ, a C-3 aminotransferase. At this stage, the sugar can undergo 
epimerization by DnmU, a C-5 epimerase resulting in configuration change from D- to L-
deoxysugar. The last sugar modification before glycoslation appears to be catalyzed by 
DnmV, a 4-ketoreductase, which yields the TDP-L-daunosamine, the sugar donor 
substrate of DnmS, a glycosyltransferase. It was also shown that the aglycon of DnmS is 
ɛ-rhodomycinone, a precursor for the anthracyclines doxorubicin and daunorubicin. 
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Scheme I-4: biosynthesis of TDP-L-daunosamine. 
 
Further analysis of the Streptomyces peucetius anthracycline gene cluster reveals 
the presence of additional sugar modifying/attachment enzymes. These enzymes 
include DnrH, a glycosyltransferase, and DnmZ, a flavoprotein homologous to ORF36 
from the everninomicin pathway. The deoxysugar gene dnrx which encodes a C3 SAM-
dependent methyltransferase was also found in the cluster. The C3-methyltransferase is 
not required for the biosynthesis of L-daunosamine because this sugar lacks C3 
methylation. Interestingly, DnrX shares high sequence similarity with the C3 
methyltransferase, ORF38, from the putative deoxynitrosugar L-evernitrose’s pathway 
(66% identity, 76% similarity). DnrX is also homologous to EvaC from the TDP-L-
epivancosamine pathway (66% identity, 78% similarity). 
The presence of these extra deoxysugar genes suggests that their encoded 
enzymes catalyze sugar modification/attachment steps for a second deoxysugar. To 
date, no anthracycline compound with two deoxysugar appendages has been isolated 
from the anthracycline producer Streptomyces peucetius, which gives rise to the 
importance of elucidating the biosynthetic route of the non-sugar acetal moiety in 
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baumycin. One possibility could be that the formation of this unusual moiety is a result 
of terminal deoxysugar degradation whereby the sugar undergoes a C-C bond cleavage, 
perhaps combined with other chemical/enzymatic steps. To resolve this intriguing 
mystery, it is essential to biochemically confirm the putative roles of these additional 
deoxysugar enzymes. The glycosyltransferase DnrH and the C-4 ketoreductase DnrX 
have well known and characterized homologues in other deoxysugar pathways hence, 
their characterization seems less attractive. Elucidation of the function of the putative 
flavin-dependent enzyme DnmZ however, seems more interesting considering its 
homology to ORF36, RubN8, and KijD3 proposed to be involved in deoxyaminosugar 
oxidation. 
 
The putative role of the flavoenzyme DnmZ 
As mentioned above, DnmZ shares high sequence homology with the proposed 
flavin-dependent enzymes ORF36, RubN8 and KijD3 proposed to be involved in 
deoxyaminosugar oxidation. For example, DnmZ shares 70% sequence similarity with 
ORF36 (59% Identity). This suggests that all of these enzymes likely catalyze a similar 
deoxyaminosugar oxidation reaction. Given the fact that there are no deoxysugar 
moieties with N-oxidation in any of the anthracycline derivatives produced by 
Streptomyces peucetius isolated to date, proposing a role for DnmZ seems difficult; 
however, one scenario can be envisioned whereby DnmZ catalyzes a deoxyaminosugar 
oxidation similar to that proposed for its homologues, whereby the resulting sugar 
 
 
26 
 
moiety undergoes further enzymatic or chemical transformations either before or after 
glycoslation. 
The biosynthetic origin of the terminal non-sugar acetal moiety in baumycin is 
unclear but one possible route for its formation is through enzymatic or chemical 
modifications of a deoxysugar precursor. The presence of extra sugar genes in the 
anthracycline gene cluster of Streptomyces peucetius supports this hypothesis.78 The C-3 
methyltransferase DnrX is likely involved in the production of the TDP-deoxyaminosugar 
substrate of the putative DnmZ enzyme. One pathway of this substrate could be 
proposed in which the DnrX activity follows the transamination by DnmJ forming the C-3 
methylated sugar. This methylation step provides a diversion from the L-daunosamine 
pathway and maybe a key requirement for subsequent deoxyaminosugar oxidation 
activity. This is consistent with the methylation at C-3 in the deoxynitrosugars L-
evernitrose, D-rubranose, and L-kijanose.13-14, 42 The subsequent steps to produce the 
DnmZ substrate could be carried out by the C-5 epimerase DnmU and a C-4 
ketoreductase yielding TDP-L-epivancosamine, a substrate precursor proposed for the 
ORF36 homologue. Amine oxidation of this sugar by DnmZ could set the stage for other 
enzymatic or chemical transformations to ultimately form baumycin (Scheme I-5) 
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SchemI-5. Proposed pathway of late-step baumycin biosynthesis including the role of DnmZ. 
 
Flavoprotein monooxygenases 
As discussed earlier and based on sequence homologies, the enzyme responsible 
for the formation of the nitro functionality in nitrosugar-containing natural products is 
likely a flavin-dependent monooxygenase. Enzymes of this family are capable of efficient 
and specific insertion of one or more oxygen atoms into an organic substrate, a reaction 
not easy to perform via traditional chemical syntheses.79 Although many chemical 
catalysts have been designed to address the difficulty of oxygenation reactions, the 
exquisite specificity and efficiency of monooxygenases remain unmatched. The 
discovery and characterization of a new flavin-dependent monooxygenase, will extend 
our knowledge of important biosynthetic pathways, support the current efforts of 
natural product structure diversification, as well as introduce new efficient biocatalysts 
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to perform difficult oxygenation reactions. Below is a brief background on flavoproteins 
with emphasis on flavin-dependent monooxygenases. 
 
Biochemistry of flavoproteins 
Flavin exists in nature in three principle forms; riboflavin (vitamin B2), flavin 
mononucleotide (FMN), and flavin adenine dinucleotide (FAD) as shown in figure I-7.80 
The FMN and FAD forms are the prosthetic groups for flavoproteins, and there are well 
characterized mechanisms for their interconversions. Flavins have bright yellow color, 
like most flavoproteins, and a characteristic UV-absorption that changes significantly 
depending on the oxidation state of the flavin. This unique spectrophotpmetric property 
allowed the study of the catalysis of many flavoproteins. Flavins undergo one electron 
reduction to give stable semiquinone radicals allowing them to mediate between the 
common two electron oxidations (e.g NAD(P)+/NAD(P)H) and one electron oxidations 
carried out by heme or iron-sulfur cluster proteins. 
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Figure I-7. Chemical structures of several flavin species. 
 
In free solution, a mixture of oxidized and reduced flavin exists in an equilibrium 
in which a certain amount of radical is formed. At pH 7, only about 5% flavin 
semiquinone radical is stabilized for a 1:1 mixture of oxidized and reduced flavin. The 
semiquinone radical can exist in a neutral or anionic form (Figure I-7). Binding to the 
enzyme can provide up to 100% semiquinone radical stabilization. For the flavin-
dependent oxidases, the bound reduced anionic flavin reacts with molecular oxygen to 
yield a caged radical pair of neutral flavin radical and superoxide (Scheme I-6). This 
radical pair can react in several pathways. The two radicals can collapse to form the C4a 
hydroperoxide anion which upon protonation forms the electrophilic C4a- 
hydroperoxide, a species that is involved in hydroxylation reactions. The peroxide 
species can undergo hydroperoxide elimination to regenerate oxidized flavin. Oxidized 
flavin can also be formed via a second one-electron transfer from the radical pair. A 
third route of the radical pair is the dissociation to its free components, flavin radical 
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and superoxide. In the oxygenation mechanism, the C4a-hydroperoxide can act as an 
electrophile such as in aromatic hydroxylations81, or when deprotonated, as a 
nucleophile such as in Baeyer-Villiger monooxygenases.82 
 
 
Scheme I-6. General mechanism of oxygenation reactions catalyzed by external flavoprotein 
monooxygenases. 
 
The monooxygenase family 
Besides flavoprotein monooxygenases, a number of other different types of 
enzymes have evolved in nature to carry out monooxygenation reactions. The 
cytochrome P450 family of monooxygenases is one of the best characterized 
monooxygenases. These are heme-containing enzymes and occur in relatively abundant 
isoforms. The catalytic mechanism of P450 monooxygenases is tightly coupled to 
substrate binding.80  Upon binding of the substrate, the heme cofactor can be reduced 
by gaining electrons from reduced flavin. The flavin is typicaly reduced by an external 
flavin reductase that accepts electrons form the NADPH coenzyme. The reduced heme is 
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then used to complete the monooxygenation of the substrate. Cytochrome P450 
monooxygenases are cabaple of hydroxylating carbon atoms regioselectively, which has 
been shown to be of great value to modify sterols and steroids. 
Other classes of monooxygenases include non-heme monooxygenases83 and 
copper-dependent monooxygenases.84 A few new types of monooxygenases have been 
discovered in recent years that do not contain the aforementioned cofactors including 
the polyketide monooxygenase ActVA-Orf6, involved in actinorhodin biosynthesis in 
Streptomyces coelicolor.81  Another example is the quinol monooxygenase YgiN, from 
Escherichia coli which oxidizes multiringed aromatic substrates without the participation 
of any cofactor.85 Aclacinomycin-10-hydroxylase, involved in anthracycline biosynthesis 
in Streptomyces purpurascens, is another rare type of monooxygenases as it depends on 
S-adenosyl-l-methionine as a cofactor.86 Flavin-dependent monooxygenases are perhaps 
the most ubiquitous of monooxygenases. They perform a wide range of 
monooxygenation reactions with high regio- and/or enantioselectivity. A brief 
background on flavin-dependent monooxygenases is disussed below. 
 
Flavoprotein monooxygenase catalysis 
Flavoprotein monooxygenases are a broad group of enzymes which share similar 
properties and mechanistic features.87 One common property of these enzymes is the 
use of NADH or NADPH to supply the reduced flavin which reacts with molecular oxygen 
to form C4a-peroxide required for oxygenation of the substrate. When protonated, the 
C4a-peroxide is a potent electrophile and can participate in hydroxylation reactions such 
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as aromatic hydroxylations.81 The flavin peroxide anion can also react as a nucleophile 
and is employed by a second subgroup of monooxygenases an example of which is 
cyclohexanone monooxygenase.88 These two subgroups of monooxygenases share 
common but distinctive properties. In most electrophilic monooxygenases, there is an 
exquisite control mechanism to ensure that the NAD(P)H cofactor is only used when the 
substrate is bound to the enzyme for oxygenation.80 Substrate binding is required for 
rapid reduction of flavin by NAD(P)H. For the nucleophilic monooxygenases, substrate 
binding is usually not required for flavin reduction but the C4a-peroxide formed upon 
reaction with O2 stabilized by the protein is only reactive in the presence of the 
substrate for oxygen transfer.89 In contrary, the C4a-hydroperoxide in electrophilic 
monooxygenases is very unstable in the absence of the substrate. 
One of the most well studied electrophilic monoxygenases is p-hydroxybenzoate 
hydroxylase and its basic mechanism appears to be followed by most members of this 
class.90 These enzymes can be studied spectrophotometrically exploiting the flavin 
absorbance and fluorescence properties.91 The mechanism of p-hydroxybenzoate 
hydroxylase monooxygenation starts with forming the flavin-NADPH-substrate ternary 
complex resulting in a long-wavelength-absorbing charge transfer between the NADPH 
as a donor and oxidized flavin as an acceptor (Scheme I-7). The next step is the 
reduction of the flavin cofactor which is also accompanied by significant change in 
absorbance and fluorescence causing another long wavelength charge transfer in which 
reduced flavin is the donor and NADP+ is the acceptor. The NADP+ species is then 
released forming the enzyme-reduced flavin-substrate complex. The resulting anionic 
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reduced flavin can then react with molecular oxygen forming the enzyme-C4a-
hydroperoxide-substrate intermediate complex. This intermediate has distinctive 
spectrum with a wavelength maximum at 380 nm which is formed with a pseudo first 
order constant directly proportional to the oxygen concentration. Oxygen transfer from 
the hydroperoxyflavin can then take place resulting in a complex of enzyme C4a-
hydroxyflavin and the non-aromatic metastable dienone (intermediate III). The following 
step is the re-aromatization to form intermediate III that includes the more stable 
hydroxylated product, a step that occurs at sufficiently slow rate that allows the 
determination of K6. The final step is the dehydration of the C4a-hydroxyflavin to recycle 
the oxidized enzyme ready for the next round of catalysis. 
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Scheme I-7 . Reaction mechanism of p-hydroxybenzoate monooxygenase. 
 
For p-hydroxybenzoate hydroxylase, it has been found that the flavin exisits in 
two different conformations: one is mostly buried in the protein core and ideally 
positioned for hydroxylation and the other is partially solvent exposed and suitable for 
reduction by NADPH.92 The mobility of the flavin cofactor has been also confirmed in the 
structural studies of the related phenol hydroxylase.93 
In nucleophilic monooxygenation, O2 reacts with reduced flavin to form the 
flavin peroxide. This is the nucleophilic flavin-oxygen intermediate that participates in 
the oxygen transfer to the substrate as in Baeyer-Villiger monooxygenases.82, 94 In 
cyclohexanone monooxygenase, the flavin C4a-peroxide formed after the reaction of 
reduced flavin with molecular oxygen can be slowly protonated to yield the C4a-
hydroperoxyflavin, or it can react with cyclohexanone as a nucleophile to form the 
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Criege intermediate which rearranges to form ɛ-carbolactam.95 The resulting 
hydroxyflavin undergoes elimination of water regenerating the oxidized flavin for next 
cycle of catalysis.96-97 The NADP+ species must be bound during the reaction to protect 
the reactive C4a-hydroperoxide. 
 
Classifications of Flavoprotein monooxygenases 
Several hundred flavoenzymes have been characterized to date.98-99 Most of 
these enzymes contain a non-covalently bound flavin in the form of FMN or FAD but 
there are some enzymes that bind the flavin cofactor covalently. Examples of flavin 
covalently bound enzymes include vanillyl-alcohol oxidase which contains FAD bound to 
a histidine residue.100 In p-cresol methyl hydroxylase, the FAD is linked to a tyrosine 
residue. It has been shown that this covalent linkage is beneficial for catalysis in the case 
of vanillyl-alcohol oxidase.101 For all internal or external flavoprotein monooxygnases 
however, the flavin cofactor is not covalently linked to the enzyme. 
Classification of the big family of flavoenzymes has been established based on 
different criteria such as the types of reactions they catalyze, cofactor requirements, 
sequence homology and structural folds. More recently, external flavoprotein 
monooxygenases have been classified by following similar criteria mentioned above. 
They were divided into six different subclasses A-F as shown in table I-2. These 
subclasses were discriminated based on sequence similarty, specific structural motifs, 
types of reactions and cofactor requirements. Structures of some prototype flavin-
dependent monoxygenases are shown in figure I-8.79 
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Table I-2 classification of external flavoprotein monooxygenases.
79
 
Class Reactions Cofactor Coenzyme Structural fold 
A Hydroxylation, 
epoxidation 
FAD NAD(P)H 1 FAD/NAD(P)-binding domain 
B Baeyer–Villiger, 
N-oxidation 
FAD NADPH 2 FAD/NAD(P)-binding domains, 
1 helical domain 
C Light emission, S-
oxidation, 
Baeyer–Villiger 
 
– 
FMN 
NAD(P)H 
 
TIM barrel 
D Hydroxylation  
– 
FAD 
NAD(P)H 
Acyl-CoA dehydrogenase (model) 
E Epoxidation  
– 
FAD 
NAD(P)H 
1 FAD/NAD(P)-binding domain 
 
F 
 
Halogenation 
 
– 
 
FAD 
NAD(P)H 
1 FAD/NAD(P)-binding domain 
1 helical domain 
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Figure I-8.
79
 Structures of several prototype flavoprotein monooxygenases. The FAD cofactor is shown 
in sticks. (A) Class A: 4-hydroxybenzoate 3-monooxygenase from Pseudomonas fluorescence (B) Class B: 
phenylacetone monooxygenase from Thermobifida fusca   (C) Class C: alkanesulfonate monooxygenase 
from Escherichia coli (no FMN cofactor was crystallized with the enzyme). (D)  Class F: tryptophan 7-
halogenase from Pseudomonas fluorescens. 
 
Class A 
Enzymes of this subclass are encoded by a single gene and contain a tightly 
bound FAD cofactor. Reduction of the FAD cofactor depends on the NADH or NADPH 
coenzyme with immediate release of the NADP+ species after reduction. Class A 
flavoprotein monooxygenases are structurally composed of a dinucleotide binding 
domain adopting the Rossman fold102 for the binding of the FAD cofactor. 
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Class A flavoprotein monooxygenases are known to catalyze epioxidation 
reactions. Squalene monooxygenase, a well-known example, is a key enzyme in the 
commited pathway for cholesterol biosynthesis which catalyzes the epioxidation of 
squalene across a C-C double bond to yield oxidosqualene.103 The activity of this enzyme 
is dependent on NADPH-cytochrome p450 reductase for reducing equivalents. 
The recently characterized Baeyer-Villiger enzyme MtOIV represents an atypical 
class A monooxygenase. This enzyme catalyzes the key-frame modifying step in the 
biosynthesis of mithramycin, an anticancer drug and calcium lowering agent. MtOIV 
cleaves a carbon-carbon bond essential for the conversion of the biologically inactive 
premithramycin B into the active drug mithramycin.104 Unlike most members of this 
class, MtOIV uses a peroxyflavin intermediate as its oxygenating species instead of the 
electrophilic hydroperoxyflavin typically used in class A flavoprotein monooxygenases. 
Another flavoprotein epioxidase that belongs to this subclass is zeaxanthin epoxidase 
specific for carotenoids with 3-hydroxyl-β-cyclohexenyl ring. This enzyme requires 
NADPH and ferrodoxin-like reductives for activity.105 
The crystal structures of enzymes of this subclass show motifs for the FAD 
binding region that resembles the β-α-β (Rossman fold) that binds the ADP moiety of 
FAD. There is no distinct domain for binding of the NADPH coenzyme consistent with its 
transient complex formation for the reduction of the flavin and rapid release as NADP+. 
Recent structural characterization of 4-hydroxybenzoate 3-monooxygenase (Figure I-8), 
a member of this subclass, showed an additional finger-print sequence containing a 
 
 
39 
 
highly conserved DG motif involved in binding of both pyrophosphate moieties of 
NADPH and FAD.106 
 
Class B 
Enzymes of class B flavoprotein monooxygenases are encoded by a single gene 
and bind tightly to the FAD cofactor. They commonly depend on the NADPH coenzyme 
as reducing equivalents and keep the NADPH/NADP+ species bound during catalysis. 
Their structure is composed of two dinucleotide binding domains adopting the Rossman 
fold for the binding of both FAD and NADPH. All members of this class are single 
component FAD-containing monooxygenases with specificity for NADPH. 
Class B flavoprotein monooxygenases are also called multifunctional 
monooxygenases because they are able to oxidize both carbon and hetero atoms. This 
class of enzymes can also be divided into three sequence related subfamilies: flavin-
containing monooxygenases107 (FMOs), microbial N-hydroxylating monooxygenases108 
(FNOs), and Baeyer-Villiger monooxygenases82 (type I BVMOs). 
Flavin-containing monooxygenases were originally named mixed function 
monooxygenases.109  They are known to play an important role in detoxification of drugs 
and foreign molecules in humans complementing the activities of cytochrome p450 
enzymes. This subclass catalyzes monooxygenation of carbon bond-reactive 
heteroatoms such as sulfur, nitrogen, phosphorous, selenium and iodine. 
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N-hydroxylating monooxygenases catalyze the N-hydroxylation of primary 
amines and hence, play an important role in the biosynthesis of bacterial siderophores. 
They have sequence homology with flavin-containing monooxygenases and require 
NADPH and FAD for activity. Unlike flavin-containing monooxygenases, N-hydroxylating 
monooxygenases show lower affinity for FAD which hindered mechanistic studies of 
their catalysis. Ornithine hydroxylase (PvdA) catalyzes the hydroxylation of the side 
chain primary amine of ornithine in the initial step of the biosynthesis of the 
Pseudomonas aeruginosa siderophore pyoverdin.108 Kinetic studies of this enzyme 
showed that binding of the substrate target is not required to trigger reduction of the 
flavin by NADPH.110 
Class B Bayer-Villiger monooxygenases (BVMOs), catalyze an atypical 
oxygenation reaction converting a ketone or an aldehyde to ester or lactone.111 One of 
the first studied enzymes of this family is cyclohexanone monooxygenase, from 
actinobacter sp. NCBBI 9871.112 This enzyme performs Baeyer-Villiger oxidations on a 
wide variety of cyclic ketones with exquisite regio- and enantioselectivity. Bayer-Villiger 
monooxygenases can be identified based on the presence of two Rossman fold domains 
for FAD and NADPH binding. It was shown that phenylacetone monooxygenase, a well-
characterized Baeyer-Villiger monooxygenase and member of this subfamily, has 
dinucleotide binding domains flanked by two helical domains which are unique for this 
type of monooxygenases.113 
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Class C 
This class belongs to multicomponent monooxygenases and commonly encoded 
by multiple genes for the monooxygenase and the reductase components. Class C 
flavoprotein monooxygenases use FMN as a cofactor which is reduced by the reductase 
component using NADPH or NADH for reducing equivalents. The general structural core 
for the monooxygenase component displays a TIM-barrel fold.114 
The most well-known examples of this class are bacterial lucifrases which are 
enzymes that emit light upon oxidation of long-chain aliphatic aldehydes.115 Luciferases 
contain two heterodimeric subunits; one is the oxygenase component and the other is 
used for the reductase activity. Other examples of this class include 2,5-diketocamphane 
1,2-monooxygenase, a type II Baeyer-Villiger monooxygenase.116 The oxygenase 
component of this enzyme consists of two subunits for FMN binding similar to 
luciferases. 
Another example is alkanesulfonate monooxygenase.117 Structural studies of this 
enzyme revealed that it has a TIM-barrel fold where the monooxygenation catalysis 
proceedes via the formation of an FMN-monooxygenase-reductase complex.118 One 
more example of this series is dibenzothiophene monooxygenase (DszC).119 This enzyme 
is involved in desulfunization of benziothiophenes. It was recently shown that DszC is 
able to utilize either FMNH(2) or FADH(2) when coupled with a flavin reductase that 
reduces either FMN or FAD.120 As discussed above, this enzyme shares moderate 
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homology with the flavin-dependent monooxygenase proposed to catalyze the 
oxidation of deoxyaminosugars. 
 
Class D 
This class of flavoprotein monooxygenases is typically encoded by two genes; 
one is for the monooxygenase and the other is for the flavin reductase component. The 
reductase component uses FAD as a cofactor and NADH or NADPH as a coenzyme. 
These enzymes are structurally homologous to acyl-CoA dehydrogenases and are mostly 
α-helical proteins. 
Members of this class are typically active on regioselective hydroxylation of 
aromatic substrates. The prototype is 4-hydroxyphenylacetate 3-monooxygenase 
(Figure I-8) which catalyzes the conversion of 4-hydroxyphenylacetate to 3,4-
dihydroxyphenylacetate.121 The oxygenase component (HpaB) introduces a hydroxyl 
group into the benzene ring of 4-hydroxyphenylacetate using molecular oxygen and 
reduced flavin, while the reductase component (HpaC) provides free reduced flavins for 
HpaB.122-123 Another example is 2,4,6-trichlorophenol monooxygenase which catalyzes 
sequential dechlorinations by oxidative and hydrolytic reactions.124 The acyl-CoA 
dehydrogenase is a sequence related model for class D flavoprotein monooxygenases 
which catalyzes fatty acid β-oxidation in the mitochondria of cells.125 
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Class E 
Class E flavoprotein monooxygenases are also encoded by two genes; the first 
gene encodes the monooxygenase component, and the second encodes the reductase 
component. They use reduced FAD cofactor generated from the reductase activity to 
mediate the monooxygenation catalysis. The reductase component can use either NADH 
or NADPH as reducing equivalents. No structures are available for enzymes of this 
subclass however, sequenece analysis indicate the presence of Rossman fold for 
dinucleotide binding and suggest that they evolved from class A flavoprotein 
monooxygenases. 
Class E flavoprotein monooxygenases are relatively rare. Styrene 
monooxygenase from Pseudomonas putida is one of the few known enzymes of this 
class.126 This enzyme oxidizes styrene in an enantioselective manner to form (S)-styrene 
epoxide with an e.e. of 99%. Mechanistic studies of this enzyme suggested that the 
reduced flavin does not have to be actively delivered by the reductase to the 
monooxygenase and the monooxygenase component can stabilize the peroxyflavin after 
binding reduced FAD and reacting with molecular oxygen.127 
 
Class F 
Class F flavoprotein monooxygenases are also encoded by two genes one for the 
monooxygenese and one for the reductase components. This class of enzymes uses 
reduced FAD generated by the reductase component which uses NADPH or NADH as 
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coenzyme for reducing equivalents. The general structural fold for FAD binding in this 
enzyme class is the Rossman fold. 
The prototype for class F flavoprotein monooxygenases is tryptophan 7-
halogenase from Pseudomonas fluorescens.128 Monooxygenation by this enzyme, and 
related halogenases, proceed via the formation of the C4a-hydroperoxyflavin 
intermediate which reacts with the chloride ion to form HOCl. In the catalysis of 
tryptophan 7-halogenase, this highly reactive nucleophile will travel through a 10 Å 
tunnel to reach and halogenate the bound tryptophan substrate regioselectively.129 In 
this respect, the chloride ion and not the substrate to be halogenated, is regarded as the 
substrate for monooxygenation. 
 
Dissertation Statement 
Deoxynitrosugar moieties are included in many isolated natural products and 
known to play significant roles in conferring biological activity. These unusual sugars are 
distributed among various scaffolds including spirotetronate antibiotics, ansamycins, 
and orthosomycins. Examples of natural products containing deoxynitrosugars include 
everninomicin, rubradirin, and kijanimicin for which the biosynthetic gene clusters have 
been recently sequenced. These recent advances in gene cluster data have enabled the 
proposal of biosynthetic pathways for the aminosugar N-oxidation to generate 
hydroxylamino-, nitroso- and nitro-sugars. Prior to our investigations, there was no 
biochemical data available for the enzymes responsible for this key oxidation to yield 
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these important deoxysugar modifications.  We have targeted the producers of 
everninomicin, rubradirin and baumycin to identify and biochemically characterize the 
enzyme(s) responsible for their deoxyaminosugar oxidations. 
Chapter II describes the initial biochemical characterization of the new 
nitrososynthase ORF36, a flavin-dependent monooxygenase, from the everninomicin 
biosynthetic pathway and its homologue RubN8, from the rubradirin biosynthetic 
pathway which reveals their roles as flavin-dependent monooxygenases in the 
deoxysugar N-oxidation pathway. Chapter III details additional biochemical 
characterization of ORF36 including solving its 3-D structure by X-ray crystallography 
and studying its substrate specificity towards several deoxyaminosugar intermediates. 
This chapter also describes 18O-incorporation experiments aimed at the investigation of 
the mechanistic details of the nitrososynthase catalysis. Chapter IV discusses the role of 
the DnmZ, a nitrososynthase homologue, from the baumycin biosynthetic pathway. The 
surprising role of this flavin-dependent nitrososynthase in a deoxysugar C-C bond 
cleavage and its confirmed role of deoxyaminosugar oxidation are also discussed. 
In summary, this work details the biochemical characterization of three flavin-
dependent nitrososynthase homologues revealing a new and important deoxysugar N-
oxidation pathway for a vast array of deoxysugar-containing natural products. The 
surprising retro-aldol activity of the nitrososynthase enzyme explains a once not 
understood pathway in the biosynthesis of baumycin-like compounds and provides new 
opportunities for utilizing this important biocatalyist in organic chemical synthesis. 
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CHAPTER II 
 
BIOCHEMICAL CHARACTERIZATION OF A NEW FLAVIN-DEPENDENT NITROSOSYNTHASE 
IN THE BIOSYNTHETIC PATHWAYS OF EVERNINOMICIN AND RUBRADIRIN 
 
Introduction 
Many bioactive bacterial natural products are appended to highly modified 
deoxysugar moities that are often important for their biological activities. These 
deoxysugar appendages are typically biosynthesized in the form of nucleotide 
diphosphate (NDP) sugars before the attachment to their corresponding aglycones by 
the activity of glycosyltransferases. Thymidine diphosphate (TDP)-activated sugars are 
the most structurally diverse class of nucleotide sugars found in nature.1 Deoxygenation 
of these sugars proceeds via a 4-keto-6-deoxy intermediate, catalyzed by a 4,6-
dehydratase, which provides the entry point into TDP-deoxysugar secondary 
metabolism in bacteria.2 Deoxyaminosugars are among the most prevalent sugars in 
sugar-containing bacterial secondary metabolites. 
The recent advances in gene cluster elucidations of glycoslated natural products 
facilitated the studies of several deoxyaminosugar pathways. Biosynthesis of 
deoxyaminosugars includes genes encoding dehydratases, isomerases, 
aminotransferases, methyltransferases, and glycosyltransferases.3 The biosynthesis of 
TDP-L-epivancosamine (Scheme I-2) is one of the well-studied deoxyaminosugar 
pathways. Five enzymes from the biosynthetic pathway of chloroeremomycin produced 
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by Amycolatopsis orientalis, have been shown to be involved in its biosynthesis starting 
from TDP-6-deoxy-4-keto-D-glucose. These enzymes were shown to perform C-2 
deoxygenation by EvaA, C-3 amination and methylation by EvaB and EvaC respectively, 
C-5 epimerization by EvaD, and C-4 ketoreduction by EvaE.4 
Oxidized congeners of deoxyaminosugars also exist in many natural products 
such as everninomicin from Micromonospora carbonacea var. Africana and var. 
aurantiaca, rubradirin from Streptomyces achromogenes var. rubradiris, and kijanimycin 
from Actinomycete Actinomadura kijaniata (Figure II-1).5-7 Hydroxyamino-, nitroso-, and 
nitrosugar derivatives of everninomicin have been isolated from the fermentation of 
some of its producers.8 It was shown that the N-oxidation of deoxyaminosugars leads to 
significant change in the antibacterial activity of the parent molecule. For example, the 
antibacterial activity against Staphylococcus aureus was 125 fold greater for the nitro- 
vs. the amino-sugar variant of everninomicin.9 This underlines the significance of 
studying the biosynthetic pathway of this important deoxsugar modification. The 
knowledge that will be gained from understanding this important N-oxidation reaction 
will impact current efforts towards natural product structure diversification, as well as 
introduce new biosynthetic enzymes to be utilized for otherwise difficult to perform 
oxidation reactions. 
The oligosaccharide everninomicin belongs to the orthosomycin class of 
antibiotics and possesses potent activity against Gram-positive and Gram-negative 
bacteria including vancomycin resistant enterococci, methicillin resistant staphylococci, 
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and penicillin-resistant streptococci.10 The structure of everninomicin is composed of 
eight deoxysugars including a terminal nitrosugar, orsellinic and dichloroisoeverninic 
acid moieties. The nitrosugar in everninomicin is called 2,3,6-trideoxy-3-C-methyl-4-O-
methyl-3-nitro-L-ribo-aldohexo-pyranose or evernitrose which is structurally related to 
D-rubranitrose present in the polyketide rubradirin and to D-kijanose in the 
spirotetronate polyketide antibiotic kijanimicin shown in figure II-1. 
 
 
Figure II-1. Chemical structures of everninomicin, rubradirin, and kijanimicin. 
 
Structurally related to everninomicins are the heptasaccharides avilamycins,11 
which lack the nitrosugar moiety and hence, were good candidates for performing 
comparative genomic analysis to identify the the nitrosugar biosynthetic gene in 
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everninomicins. These analyses identified a cassette of genes most of them having 
homologues in the biochemically characterized L-epivancosamine pathway in the 
biosynthesis of chloroeremomycin. The orf36 gene from M. carbonacea var. Africana 
(orf42 from M. Var. aurantiaca) was proposed to encode a flavin-dependent oxidase 
responsible for the N-oxidation of a TDP-aminosugar precursor to form the C-3 nitro 
group present in the nitrosugar moiety in everninomicin.12 
Homologues of the putative ORF36 enzyme were also found in the recently 
sequenced gene clusters of the nitrosugar-containing compounds rubradirin and 
kijanimicin. ORF36 is 63% identical to RubN8 from the rubradirin biosynthetic pathway 
and 65% identical to KijD3 from the kijanimicin pathway. The high sequence similarities 
among these enzymes and their moderate homology to flavin-dependent enzymes, 
suggests that they play roles as N-oxidases in the biosynthesis of the nitrosugar moiety 
in their corresponding natural product pathways. 
Despite this striking sequence-based analysis, biochemical characterization of 
these putative flavin-dependent enzymes in the N-oxidation of aminosugars has not 
been previously performed. In this study, we targeted the producers of everninomicin 
and rubradirin and amplified the two putative flavin dependent oxidase genes orf36 
from M.carbonacea var. africana and rubn8 from S. achromogenes var. rubradiris. 
Genes were amplified from their corresponding genomic DNA  by the polymerase chain 
reaction (PCR). The PCR products were subcloned into a pET28a expression plasmid and 
transfomed to E.coli BL21(DE3) via electroporation. The proteins were overexpressed 
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and purified to homogeneity by Ni+2-affinity chromatography. A close analog to the 
authentic substrate evernosamine (TDP-L-epivancosamine), lacking the C4 O-
methylation, was prepared in situ by a Staudinger reduction13 of a synthetic azide 
congener with tris(2-carboxyethyl)phosphine. Next, we developed an LC-ESI-MS method 
to assay the activity of the putative oxidases with the synthetically prepared TDP-L-
epivancosamine. Besides the putative oxidase and the substrate TDP-L-epivancosamine, 
the assay included FAD, NADPH and an external flavin reductase from Photobacterium 
fischeri14 to generate reduced flavin required for catalysis. 
 
Results and discussion 
 
Comparative genomics 
Avilamycins are heptasaccharides with structures very similar to everninomicins 
but lacking the nitrosugar moiety (Figure II-2). Another main structural difference is the 
lack of the terminal orsellinic acid moiety present in everninomicins which is replaced by 
an acetyl group in avilamycins. The availability of gene cluster data for these 
oligosaccharides from different bacterial producers facilitated a comparative genomic 
analysis to identify the genes responsible for the biosynthesis of the nitrosugar moiety 
in everninomicins. These analyses were performed on two everninomicin producers: 
Micromonospora carbonacae var. aurantiaca and Micromonospora carbonacea var. 
africana, and two avilamycin producers; Streptomyces viridochromogenes and 
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Streptomyces mobaraensis.12 This comparative genomic approach identified a cassette 
of genes as candidates for the biosynthesis of the nitrosugar evernitrose, homologues of 
which are found in the biosynthetic pathway of the aminosugar L-epivancosamine from 
the chloroeremomycin biosynthesis. A list of these genes was shown in table I-1. 
 
 
Figure II-2. Chemical structures of avilamycin and everninomicin. 
 
The L-epivancosamine moiety in chloroeremomycin is an aminosugar structurally 
related to the nitrosugar evernitrose15 lacking the C3 N-oxidation and the C4 O-
methylation (Figure II-3); therefore, most enzymes responsible for its biosynthesis are 
shared with those in the L-evernitrose’s biosynthetic pathway.4 Additional genes were 
identified in the everninomicin clusters that likely account for the C4 O-methylation and 
the C3 N-oxidation. The orf41 gene from the EVEA cluster encodes a SAM dependent C4 
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O-methyltransferase most likely responsible for the methylation of the C4 hydroxyl 
group to form the C4 methoxy group in L-evernitrose. 
 
 
Figure II-3. Chemical structures of L-epi-vancosamine and L-evernitrose. 
 
Three additional genes encoding putative oxidases in the everninomicin clusters 
were also identified in this comparative genomic analysis namely, orf36, orf18, orf19 
from the EVEA cluster. Orf18 has a reasonable homology to RNA-methyltransferase 
genes, whereas orf19 is homologous to copper-dependent oxidase genes involved in 
primary metabolism; therefore, neither is likely to be involved in the biosynthesis of the 
nitrosugar moiety in everninomicin. The only remaining and likely oxidase responsible 
for the N-oxidation an aminosugar precursor is orf36 in the EVEA cluster. This gene has 
moderate sequence homology with the flavin-dependent monooxygenase 
dibenzothiophene oxidase DszC, which has been shown to oxidize a sulfide group to a 
sulfone via a sulfoxide intermediate.16 The encoded ORF36, RubN8 and KijD3 proteins 
also shared moderate sequence similarity (~25%) with the acyl-CoA dehydrogenase 
family of enzymes. Acyl-CoA dehydrogenases are also flavin-dependent enzymes and 
are used as a structural model for class-D flavin-dependent monooxygenases.17 
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Preparation of the putative oxidases and their aminosugar substrate 
We targeted the producers of everninomicin18 and rubradirin19 to prepare the 
putative enzymes responsible for the aminosugar oxidation to form the nitro group in 
their deoxynitrosugar moieties. The genes orf36 from Micromonospora var. africana and 
rubn8 from Streptomyces achromogenes var. rubradiris were proposed to encode a 
flavin-dependent monooxygenase responsible for the N-oxidation of a TDP-activated 
deoxyaminosugar precursor.20-21 We amplified these genes using the genomic DNA of 
their producers via the polymerase chain reaction (PCR), and cloned the resulting gene 
products into the NdeI/HindIII site of the expression plasmid pET28.22 The gene products 
were designed to encode an N-terminal hexahistidine tag to facilitate the protein 
purification using a Ni2+-affinity column. The recombinant plasmids were transformed to 
the E.coli strain BL21 (DE3) for overexpression.  Both proteins were found to require 0.1 
mM β–D-1-thiogalactopyranoside (IPTG) and the best expression temperature was 
found to be 28 °C. Analysis of the purified proteins by SDS-PAGE showed protein bands 
consistent with their calculated molecular weight (~44 kD) as shown in figure II-4 for the 
Ni2+-purified RubN8. 
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Figure II-4. SDS-PAGE gel of Ni2+-affinity purified RubN8. 
 
A close substrate analogue, (5:1 β/α )-TDP-L-epivancosamine, in which the C-4 
methoxy group is replaced by a hydroxyl group, was prepared by in situ Staudinger 
reaction of its synthetic azide congener with tris(2-carboxyethyl)phosphine (TCEP) 
(Figure II-5). The azide congener was kindly provided to us by Prof. Daniel Kahne’s 
research group at Harvard University.23 We expected TDP-L-epivancosomine to be a 
candidate substrate for the amine oxidation by the proposed oxidases although it lacked 
the C4 O-methylation because an everninomicin variant, in which the methoxy group at 
C-4 of the nitrosugar moiety is replaced by a hydroxyl group, was also isolated from the 
fermentation of M. micromonospora var. africana.8 HPLC-MS analysis of the above 
mentioned Staudinger reaction showed that 95% of the (5:1)-β/α mixture of TDP-L-
epivancosamine azide could be reduced to L-TDP-epi-vancosamine providing the 
aminosugar substrate for ORF36 and RubN8 biochemical characterization. 
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Figure II-5. LC-ESI-MS analysis of the Staudinger reduction of the synthetic (5:1 β/α)-azido congener of 
TDP-L-epi-vancosamine by TCEP. 
 
Enzymatic activities of ORF36 and RubN8 
As discussed in the introduction, ORF36 and RubN8 from the everninomycin and 
rubradirin biosynthetic pathways, respectively, are proposed to be flavin-dependent 
enzymes responsible for the N-oxidation of TDP-activated aminosugar, which ultimately 
produces its nitrosugar congener.  These putative oxidases share moderate homology 
with the flavin-dependent enzyme DszC, which oxidizes dibenzothiophene (DBT) to DBT 
sulfone (DBTO2).24  This two-step oxidation requires flavin mononucleotide (FMN), 
NADPH, and an external flavin reductase to provide reduced flavin which, in turn, 
provides reducing equivalents and mediates the monooxygenation. Reduced flavin 
reacts with molecular oxygen to form the C4a-hydroperoxyflavin, a reactive oxygen 
species that is responsible for the electrophilic oxidation of the substrate.25  The 
oxygenation results in the incorporation of one oxygen, usually as a hydroxyl group, and 
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the formation of reduced C4a-hydroxy flavin.  The hydroxyflavin readily loses a water 
molecule to generate the oxidized flavin required for a subsequent round of catalysis. 
With flavin-dependent enzyme cofactor requirements taken into consideration,26 
we designed an enzymatic assay for both ORF36 and RubN8 to reconstitute their 
activities in vitro. In addition to the putative oxidase, the assay included FAD, 
Photobacterium fischeri flavin reductase, and NADPH. Considering the possibility that 
reactive oxygen species (ROS) may oxidize TDP-L-epi-vancosamine, all enzymatic 
reactions were also performed in the presence of a catalytic excess of catalase and 
superoxide dismutase. The catalase catalyzes the decomposition of hydrogen peroxide 
to oxygen and water while the superoxide dismutase catalyzes the dismutation of the 
superoxide anion into oxygen and hydrogen peroxide.27 
Product formation was assayed by electrospray HPLC-MS using a graphitic 
Hypercarb column in the negative ion mode, which effectively separated all TDP 
products.28 As shown in Figure II-6, time course assays revealed rapid disappearance of 
TDP-L-epivancosamine (m/z) 544), transient appearance of intermediary hydroxylamine 
(m/z) 560), and ultimately the formation of the nitroso compound TDP-epi-
vancosonitrose (m/z) 558 and a species of +18 mass units at  (m/z) 576. Of note, only 
the β anomer of TDP-L-epivancosamine was oxidized, consistent with the catalytic 
competence known for the TDP-sugar-modifying enzymes. The formation of the TDP-
nitrosugar congener was only observed at slow rates ambiguous to be counted as an 
enzymatic conversion. Control reactions omitting ORF36/RubN8, FAD, or NADPH 
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produced no detectable oxidation products, which validated the authenticity of the 
RubN8’s and ORF36’s activities. 
 
 
Figure II-6. HPLC-ESI-MS chromatograms of the time course of RubN8 oxidation reaction. 
 
Tandem MS fragmentation of selected product ions (Figure II-7) showed diagnostic 
fragmentation patterns of the hydroxylamino intermediate and the nitroso product 
including the loss of TDP anion (m/z 401) and it’s dehydrate (m/z 383).  Another 
fragment ion with low intensity representing the loss of the hydroxylamino group from 
the TDP-3-hydroxyaminosugar intermediate was observed at m/z 527. 
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Figure II-7. Tandem MS spectra of the nucleotide-hydroxyaminosugar intermediate (above) and the 
nucleotide-nitrososugar product (below) from RubN8 oxidation reaction. 
 
Proposed mechanism of nitrososynthase 
Based on our biochemical data obtained in this work, a minimal mechanism can 
be proposed for the catalysis of this new nitrososynthase enzyme (Scheme II-1). The 
four-electron flavin-mediated oxidation of an amine to a nitroso functional group likely 
involves two monooxygenation steps. The first step involvs the oxidation of the  
aminosugar to the corresponding hydroxylamine  via a flavin monooxygenase 
mechanism similar to that of L-ornithine N5-oxygenase29 from pyoverdin biosynthesis 
and p-hydroxybenzoate hydroxylase from Acinetobacter calcoaceticus .30 In this 
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mechanism, we propose that bound reduced FAD, generated by flavin reductase, reacts 
with molecular oxygen to form flavin C4a-hydroperoxide, which acts as the electrophilic 
oxidizing species in the formation of the hydroxylamino sugar. The resulting flavin-C4a-
hydroxide loses a water molecule recycling the oxidized FAD cofactor. In the second 
step, the oxidation of the hydroxylamino sugar intermediate to the nitroso sugar may 
proceed via an iterative oxidative process in which the bound C4a-hydroperoxy flavin 
mediates another monooxygenation to ultimately form the nitroso sugar. This requires 
the regeneration of reduced flavin by the flavin reductase/NADPH for the second round 
of oxidation. To confirm FAD recycling, reactions were performed by stoichiometrically 
limiting NADPH. The formation of the hydroxylamine was observed, but no further 
oxidation products appeared until additional NADPH was added to the reaction, 
suggesting further reducing equivalents are required for the second monooxygenation 
step via the supplied NADPH/flavin reductase enzyme. 
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Scheme II-1. Proposed pathway for the nitrososynthase oxygenation reaction. Pathway B was proposed 
to be not likely to occur, because limiting the NADPH coenzyme resulted in the formation of only the 
hydroxylamino intermediate. 
 
Conclusion 
In this study, the proposed flavin-dependent enzymes RubN8 and ORF36 were 
shown to be capable of oxidizing a synthetic aminosugar substrate analogue (TDP-L-
epivancosamine), lacking the C4 O-methylation, to its corresponding nitroso congener. 
The oxidation appears to proceed via a hydroxylamino intermediate and requires 
reduced FAD generated by an external flavin reductase with NADPH as reducing 
equivelent. Although the C4 O-methylation in the authentic aminosugar substrate may 
affect subsequent oxidation reactions, our data are consistent with previous studies 
showing that the nitroso variant of rubradirin is the direct oxidation product when 
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fermentations were performed in the absence of ambient light. Oxidation to the nitro 
group remains to be further investigated and possible pathways may include latent 
(photo)chemical process or endogenous reactive oxygen species (ROS).31 
Taken together, the biochemical data presented in this work provide the first 
evidence for a new class of flavin-dependent monooxygenase we termed a 
nitrososynthase responsible for the N-oxidation of deoxyaminosugars in vast array of 
nitrosugar-containing natural product pathways. The observed monooxygenase activity 
of RubN8 and ORF36 is direct biochemical evidence for the deoxyaminosugar N-
oxidation in the rubradirn and the everninomicin pathways, respectively, and can 
explain the roles of nitrososynthase homologues in related biosynthetic pathways. This 
study provided the basis for more detailed biochemical characterization of this 
important class of enzymes and their roles in several biosynthetic pathways. 
 
Materials and methods 
 
Bacterial strains, Plasmids and Material 
All reagents were obtained from Sigma-Aldrich Corporation and used without 
further purification unless otherwise noted. E. Coli TOP10 and BL21(DE3) competent 
cells were obtained from Invitrogen Inc. (Carlsbad, CA) and  Novagen  (Madison, WI), 
respectively. Restriction endonucleases and T4 DNA ligase were obtained from New 
England Biolabs (Ipswich, MA). The pET28a expression vector was purchased from 
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Novagen Inc. Taqplus DNA polymerase was purchased from Stratagene Inc. (La Jolla, 
CA). DNA primers were obtained from Operon Biotechnologies (Huntsville, AL). 
 
Preparation of the azido sugar substrate 
The azido congener of TDP-L-epivancosamine shown in figure II-5, was prepared 
by Prof. Daniel Kahne’s research group at the Department of Chemistry and Chemical 
Biology, Harvard University. The following procedure was provided: Solvents were 
reagent grade and were further dried when necessary.  Analytical thin-layer 
chromatography was performed on glass plates precoated with silica gel (250 μm, 
Sorbent Technologies), with detection by UV and/or spraying with H2SO4 (50%).  Flash 
chromatography was carried out on silica gel (60 Å, 32-63 μm), purchased from Sorbent 
Technologies.  Analytical HPLC of synthetic reaction mixtures was performed on a 
Hewlett-Packard 1100 series instrument using a Phenomenex Luna 5 μm C18 column 
(250 mm x 4.6 mm).  Compounds bearing a thymidine chromophore were monitored at 
an absorbance of 270 nm.  Synthetic reactions were monitored by HPLC using gradient A 
(linear gradient from H2O/0.1% NH4HCO3 to 100% MeOH/0.1% NH4HCO3 over the 
course of 25 min).  Preparative HPLC was performed on a Varian ProStar instrument 
using a Phenomenex Luna 10 μm C18 column (250 mm x  50 mm).  NMR spectra were 
recorded on Varian Inova 400 or 500 MHz spectrometers.  Mass spectra (ESI) for 
synthetic compounds were obtained using an Agilent Technologies LC/MSD instrument 
(Model #G1956B). 
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Thymidine 5'-(3-amino-2,3,6-trideoxy-3-C-methyl-a,b-l-arabino hexopyranosyl 
diphosphate), TDP a,b-epi-L-vancosamine azide (5). The protected TDP epi-vancosamine 
(reference:  Org. Lett., Vol 6, 2004) (38 mg, 60 μmol) was dissolved in MeOH/H2O/Et3N 
(2:2:1, 4 mL) and stirred at room temperature for 16 h. Following evaporation, the 
residue was redissolved in MeOH/H2O (2:1, 2 mL) and purified by reversed-phase HPLC. 
(18 mg, 92%) was obtained as its ammonium salt, tR = 9.0 min, method A. 1H NMR (400 
MHz, D2O): 2.25b: δ = 7.62 (s, 1 H, 6-H), 6.24 – 6.21 (m, 1 H, 1'-H), 5.22 – 5.17 (dt, J1,2b 
= J1,P = 9.0, J1,2a = 2.1 Hz, 1 H, 1"-H), 4.47 (m, 1 H, 3'-H), 4.02 (m, 3 H, 4'-H, 5'-H2), 
3.52–3.47 (m, 1 H, 5"-H), 3.16 (d, J4,5 = 10 Hz, 1 H, 4"-H), 2.22 - 2.08 (m, 2 H, 2'-H2) 2.07 
(d, ,J2a,2b = 12.6 Hz, 1 H, 2"-Ha ), 1.71 (s, 3 H, thymidine CH3), 1.56-1.51 (dd, J1,2b = 
9.0, J2a,2b = 12.6 Hz, 1 H, 2"-Hb), 1.25 (s, 3 H, 3"-CH3), 1.13 (d, J5,6 = 6.4 Hz, 3 H, 6"-H3); 
31P NMR (162 MHz, CD3OD): δ = –10.61, –12.82. LRMS (ESI) for C17H27N5O13P2 
(570.12): 571 [M–1H]–. 
 
Cloning and overexpression of ORF36 
This protein was cloned, expressed and purified by Dr. Yunfeng Hu. The gene 
encoding ORF36 was amplified from genomic DNA of Micromonospora carbonacea var. 
africana (NRRL 15099) using the following primers: 5'-
GCACATATGGCGGCGGATCTTCGCGC3' and 5'-TTGAAGCTTTTATTACGCCGA 
GGTCCGGGAGC-3' (NdeI and HindIII restriction enzyme sites underlined). PCR reactions 
were carried out using Taqplus DNA polymerase according to the manufacture protocol. 
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Subcloning of orf36 into the NdeI/HindIII sites of pET28a yielded the recombinant 
plasmid pET28-36N for expression as an N-terminal hexahistidine fusion protein. 
Plasmid pET28-36N was transformed into E. Coli BL21(DE3) for heterologous expression 
of ORF36. Cultures of E. Coli BL21(DE3)/pET28-36N was grown at 37°C to an OD600 of 
0.6, at which point the culture was induced with 0.1mM isopropyl-beta-D-
thiogalactopyranoside (IPTG) and grown an additional 6 hours at 28°C. Cells were 
harvested by centrifugation and stored at -80°C until needed. IPTG induced E. Coli 
BL21(DE3)/pET28-36N cells were resuspended in buffer A (20 mM Imidazole, 0.5M NaCl, 
20mM Tris-Cl, pH 7.5) and lysed by sonication. The lyate was loaded onto a charged 5-ml 
Histrap crude column (Amersham Biosciences) and purified by FPLC at a flow rate of 
5mL/min. The column was washed with buffer A (20 mM Imidazole, 0.5M NaCl, 20 mM 
Tris-Cl, pH 7.5) and buffer B (500 mM Imidazole, 0.5M NaCl, 20 mM Tris-Cl, pH 7.5) using 
a step gradient. Fractions containing ORF36 were analyzed by SDS-page. The protein 
was desalted via a desalting column (HisTrap) using buffer C (20 mM Tris-Cl, 1mM 
dithiothreitol and 5% glycerol, pH 7.5) and stored at -80 °C until assayed. 
 
Cloning and overexpression of rubN8 
The gene encoding RubN8 was amplified from Streptomyces achromogenese var. 
rubradiris (NRRL3061) genomic DNA. The following PCR primer pairs were used to clone 
the gene into the NdeI/HindIII site of pET28a (restriction sites underlined):  5’-
TCCATATGA-TGGAGACGGAACAGGCCCC-3’ and 5’-TCAAGCTTTCACCGGCTGTCCACCGGC-
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3’. Restriction-digested PCR products were subcloned into the digested pET28a vector to 
yield pET28a-his6-RubN8.  Cultures of E.coli BL21(DE3) transformants (1 L Luria broth 
(LB) media with 50 µg/mL kanamycin) were grown  at 37 °C to an OD600 of 0.6 at which 
point the cultures were induced with 0.25 mM isopropyl-1-thio-β-D-galactoside (IPTG) 
and grown for additional 16 h. Cells were harvested by centrifugation and frozen at -
80°C until needed. Frozen cells were resuspended in binding buffer [20 mM imidazole, 
0.5 M NaCl, 20 mM sodium phosphate (pH 7.5)] and lysed by sonication. After 
clarification by centrifugation at 10000g, the lysates were loaded onto Ni2+-charged 5-
mL HisTrap column and purified using FPLC (Amersham Biosciences) with a flow rate of 
5 mL/min. The column was washed with 50 mL of binding buffer and proteins were 
eluted with a gradient of imidazole (20-500 mM imidazole). Fractions containing the 
proteins were analyzed by SDS-PAGE, pooled, concentrated to 5 mL and desalted by 
FPLC using a 5 mL size exclusion desalting column (HiTrap) from Amersham Biosciences. 
The column was equilibrated with 50 mL desalting buffer [ 20 mM Tris.HCl, 5%glycerol, 1 
mM DTT, pH 7.5], the proteins were then loaded onto the column (maximum of 1.5 mL)  
and eluted at a flow rate of 5 mL/min. Fractions containing the protein were analyzed 
again by SDS-PAGE and stored at -80 °C until assayed. 
 
Preparation of L-TDP-epi-vancosamine 
L-TDP-epi-vancosamine (4-O-desmethyl L-TDP-evernosamine) was prepared by 
reduction of a synthetic azide congener (0.5mM) with 1mM tris(2-
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carboxyethyl)phosphine (TCEP) in 20 mM Tris-Cl (pH 7.5) at 22°C for 24 hours.  Amino 
sugar was stored in small aliquots at -80 °C for assays. HPLC/MS, performed for L-TDP-
epi-vancosamine enzymatic reaction described below, indicated that the extent of 
reaction was > 96%. 
 
ORF36/RubN8 enzymatic reactions 
ORF36 activity was assayed in 20 mM Tris-HCl buffer (pH 7.5) in the presence of 
0.4 – 2 mM NADPH, 30 µM FAD, 250 µM L-TDP-epi-vancosamine, 0.001 mg/ml of the 
NAD(P)H oxidoreductase of Photobacterium fischeri (Boehringer Mannheim, Mannheim, 
Germany) and 0.5mg/ml of ORF36 per 50 µl. Reactions were maintained  at 30 °C. 
Solutions of the substrate L-TDP-epi-vancosamine, flavin adenine dinucleotide 
(FAD) and nicotinamide adenine dinucleotide phosphate (NADPH), were made in 20 mM 
Tris-HCl pH 7.5.  RubN8 was aliquoted in storage buffer [20 mM Tris.HCl, 5% glycerol, 1 
mM DTT, pH 7.5]. Flavin reductase was stored in 40% glycerol, 1 mM EDTA, 0.1 mM DTT 
and 50 mM potassium phosphate, pH 7.0. The catalase and superoxide dismutase 
enzymes were made in [20 mM Tris.HCl 40% glycerol, pH 7.5].      In a total volume of 50 
µL, 250 µM of the substrate, L-TDP-epi-vancosamine, was incubated with 30 µM FAD, 1 
U/mL catalase, 1 U/mL superoxide dismutase, 0.001 mg/mL flavin reductase, and 2 mM 
NADPH. Control assays lacking RubN8, FAD or NADPH were performed. The reaction 
was initiated by the addition of 0.5 mg/mL RubN8 or 0.5 mg/mL ORF36. The time course 
of the reaction was followed by HPLC/MS at 30 °C. 
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HPLC/MS assay for L-TDP-epi-vancosamine reaction 
The oxidation of L-TDP-epi-vancosamine to corresponding products was carried 
out using an Agilent 1100 HPLC system (Agilent, Palo Alto, CA), comprising a binary 
pump and refrigerated autosampler. Mass spectrometry was performed by using a 
ThermoFinnigan (San Jose, CA) LCQ Quantum Deca XP three-dimensional Ion Trap Mass 
Spectrometer equipped with an API electrospray ionization source outfitted with a 50 
μm I.D. deactivated fused silica capillary. The injection volume was 5 μl. Products were 
detected using a Thermo Hypercarb column (3mm × 5cm). Mobile phases were: (A) H2O 
with 50 mM ammonium acetate and 0.1% (v/v) diethylamine and (B) H2O/acetonitrile 
(5:95) with 50 mM ammonium acetate and 0.1% (v/v) diethylamine. Gradient conditions 
were as follows: 0-5 min, B = 15%; 5-15 min, linear gradient to 35% B; 15 to 16 min, 
linear gradient to 100%B; 16 to 21 min, hold B = 100%; 21 to 22 min, linear gradient to 
15% B; 22-30 min, B = 15%.  The flow rate was maintained 0.3 ml/min. The mass 
spectrometer was operated in the negative ion mode, and the electrospray needle was 
maintained at 3,400 V. The ion transfer tube was operated at -47.50 V and 275 °C. The 
tube lens voltage was set to -46 V. The mass spectrometer was operated in full scan 
mode. Full scan spectra were acquired from m/z 50.0 to 1500.0 full and product ion 
scans as follows: 544→155-548 with collision energy of 30%; 558→155-560, with 
collision energy of 30%; 560→155-562 with collision energy of 30%; 544→155-548 with 
collision energy of 30%; 570→155-575 with collision energy of 30%. Data were acquired 
in profile mode. The following optimized parameters were used for the detection: N2 
sheath gas 46 psi; N2 auxiliary gas 13 psi; spray voltage 3.4 kV. 
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Chapter III 
STRUCTURAL AND MECHANISTIC STUDIES OF THE NITROSOSYNTHASE ORF36 FROM 
MICROMONOSPORA CARBONACEA VAR. AFRICANA 
 
Introduction 
The experiments outlined in Chapter II describing the activity of the 
nitrososynthases ORF36 from Micromonospora carbonacea var. africana, and RubN8 
from Streptomyces achromogenes var. rubradiris, formed the basis for further 
biochemical characterization of this new class of flavin-dependent monooxygenases. 
ORF36 and RubN8 were shown to catalyze the 2-step N-oxidation of a close substrate 
analog, TDP-L-epivancosmine, resulting in the formation of its nitroso congener via a 
hydroxylamino intermediate.1 Although no enzymatic oxidation to the nitro group was 
observed, the nitroso sugar product is consistent with previous studies with rubradirin, 
which suggested that the nitro oxidation state is a result of photo oxidation of the 
nitroso group.2 
Several enzymes in nature catalize the N-oxidation of amines. For example, the 
Rieske, aminopyrrolnitrin N-oxygenase (PrnD) catalyzes the unusual flavin-dependent 
oxidation of an arylamine to an arylnitro group.3  Another example is the non-heme di-
iron monooxygenase (AurF) from Streptomyces thioluteus which catalyzes the formation 
of unusual polyketide synthase starter unit p-nitrobenzoic acid from p-aminobenzoic 
acid in the biosynthesis of the antibiotic aureothin.4 N-Oxidation can also be catalyzed 
by P450 enzymes5 and several single-component flavin monooxygenases.6 
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Our preliminary biochemical characterization of ORF36 and RubN8 showed that 
the nitrososynthase is a flavin-dependent monooxygenase.1   Flavin-dependent 
monooxygenases are a diverse class of enzymes capable of efficient and specific 
insertion of one or more oxygen atoms into an organic substrate, a reaction that is 
difficult to achieve via standard chemical synthesis. Oxidation reactions catalyzed by 
flavin-dependent monooxygenases include hydroxylation, halogenation, sulfoxidation, 
and Baeyer-Villiger oxidation.7 The double N-oxidation of aminosugars by the 
nitrososynthase represents a new addition to this set of reactivities. This new enzyme 
may be best classified as Class D flavin-containing monooxygenase based on its 
sequence homology with acyl-CoA dehydrogenases, which are sequence models for this 
class.  Members of class D flavin-containing monooxygenases typically hydroxylate 
aromatic substrates.8-11 Interestingly, nitrososynthases have more sequence similarities 
with acyl-CoA dehydrogenases (~25%) than with flavin-containing monooxygenases 
(~15%) contrary to their biochemical evidence suggesting a monooxygenase activity. 
Class D flavoprotein monooxygenases are typically encoded by two genes; one 
encodes the monooxygenase while the other encodes the flavin reductase component. 
The reductase component uses FAD as a cofactor and NADH or NADPH as a coenzyme. 
These enzymes are structurally homologous to acyl-CoA dehydrogenases and are mostly 
α-helical proteins. In our previous biochemical characterization of the nitrososynthase 
ORF36, it was shown that its activity requires flavin and NADPH with significant 
enhancement reached upon the inclusion of an external flavin reductase.1  Furthermore, 
ORF36 was shown to display weak, reversible binding for oxidized flavin. ORF36 was also 
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shown to utilize both FAD and FMN as its flavin cofactors with preference to FAD. This 
cofactor promiscuity was observed in the class D flavoprotein monooxygenase 4-
hydroxyphenylacetate monooxygenase from Acinetobacter baumannii.12 
Our recent biochemical characterization of the nitrososynthase ORF36 was 
impeded by several challenges including the lengthy synthesis of the TDP-sugar 
substrate, its storage instability, and the low affinity of the flavin cofactor which 
typically provides a convenient spectrophotometric monitoring of the flavin cofactor’s 
redox states. To address these challenges, we developed a modified in vitro procedure 
utilizing six purified enzymes to generate the close substrate analog TDP-L-
epivancosamine, lacking the C4 O-methylation, in sufficient quantities to study enzyme 
turnover of this substrate and its TDP-aminosugar precursors in its biosynthetic 
pathway.13 Additionally, we studied the nitrososynthase oxidation reaction with the 
biogenic TDP-L-epivancosamine under 18O2 and observed oxygen incorporation into the 
oxidation products and intermediates which provided more evidence for a 
monooxygenase mechanism. Finally, in collaboration with Prof. Tina Iverson’s research 
group, Dr. Jessica Vey solved the 3-D structure of ORF36 by X-ray crystallography, which 
revealed important chemical and physical constraints of the protein scaffold that houses 
the flavin-dependent double N-oxidation of the TDP-aminosugar.14 Taken together 
these studies provided important biochemical details of the nitrososynthase responsible 
for the N-oxidation of deoxyaminosugars in everninomicin and related nitro-sugar 
containing bioactive natural products. 
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Results 
 
Substrate preference of ORF36 
An ever-increasing number of nitrososynthase homologs have been deposited to 
the GenBank corresponding to their oxidative role as flavin-dependent enzymes in the 
biosynthesis of many nitrosugar-containing natural products.15-17 The structural 
modifications of the nitrosugar moiety in these compounds are mostly conserved with 
notable functional variability at C-4 position which can be found as hydroxyl, O-methyl 
or N-carbamoyl group. Functional variability also includes the C-5 position leading to 
possibilities between the sugar’s D and L configurations.15-17 The diversity of structures 
of the aminosugar precursor substrates is in contrast with the high sequence identity 
between all the nitrososynthase homologues in several nitrosugar pathways18, which 
prompted us to investigate whether the reported nitrososynthases act on a common 
intermediate biochemically upstream of the last biosynthesized aminosugar substrate in 
the corresponding pathways. 19 
To address this possibility and further investigate the timing of aminosugar 
oxidation to ultimately yield the nitroso functionality, we reconstituted the biosynthetic 
pathway for the aminosugar TDP-L-epi-vancosamine using enzymes obtained by the 
Walsh group from the chloroereomycin pathway13, and studied the activity of ORF36 
with two additional upstream TDP linked C4-keto-3-aminosugar intermediates in this 
pathway (Figure III-1). We were unable to isolate enough quantities from this multistep 
enzymatic synthesis of these TDP-sugar intermediates to perform Michaelis-Menten 
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kinetics due to their low storage stability; however, we were able to compare turnover 
of substrates at identical, titrated substrate concentrations (30 µM). 
 
 
Figure III-1. Pathway utilized for biochemical synthesis of TDP-L-epi-vancosamine and the TDP-4-keto-3-
amino sugar precursors. This figure is taken from reference 14 in which the author of this document is a 
coauthor.  
 
 
Analysis of the enzyme assays by HPLC-MS showed that all potential aminosugar 
substrates displayed a degree of chemical competence for single oxidation to 
hydroxylamine, but only TDP-L-epivancosamine underwent double oxidation to form 
both the hydroxylamine and subsequently the nitrososugar product (Figure III-2). 
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Figure Figure III-2. HPLC-ESI-MS traces of ORF36 oxidation reactions with three potential amino sugar 
substrates. (A) TDP-L-epivancosamine  (m/z 544) at 0 min (blue) and 100 min (green), hydroxylamine 
intermediate (m/z 560) at 15 min (red), and nitroso product  (m/z 558) at 100 min (purple). (B) TDP-L-3-
amino-4-keto sugar substrate (m/z 542) at 0 min (blue) and 100 min (green) and hydroxylamine 
intermediate  (m/z 558) at 100 min (purple). (C) TDP-D-3-amino-4-keto sugar substrate (m/z 542) at 0 
min (blue) and 100 min (green) and hydroxylamine intermediate  (m/z 558) at 100 min (purple). This 
figure is taken from reference 14 in which the author of this document is a coauthor.  
 
The two 3-amino-4-keto sugar precursors of TDP-L-epivancosamine (Figure III-
2B,C) differ in the configuration at C-5 with the first biosynthesized ketosugar having a D 
configuration and upon the activity of EvaD, its L congener is formed. The TDP-L-3-
amino-4-keto sugar (Figure III-2B) was assayed by including a catalytic excess of the C-5 
epimerase (EvaD) in the nitrososynthase oxidation reaction. This TDP-L-aminosugar 
substrate was rapidly oxidized to its hydroxylamino congener but did not further oxidize 
to other species under the ORF36 assay conditions (Figure III-2B). The TDP-D-3-amino-4-
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keto sugar precursor was also oxidized to its hydroxylamino oxidation state, but at a 
substantially slower apparent rate than when the epimerase was added to reactions 
(Figure III-2C). This is in agreement with its recently reported partial oxidation by KijD3, 
which likewise only evidenced the formation of a hydroxylamine.18 Unlike these studies, 
however, we did not observe additional peaks at m/z = 527 rationalized by the authors 
as a fragment of the hydroxylamine.  This mass corresponds to a reduction product, the 
identity of which remains undetermined. In our ORF36 assays, the two 4-keto D- and L-
aminosugar substrates were oxidized to their corresponding hydroxylamino compounds 
and no other detectable TDP-sugar decomposition products were apparent by MS or 
MS/MS analysis. 
The oxidation of TDP-L-epivancosamine generated from the reconstitution of its 
natural biosynthetic pathway confirmed our previous results using the chemically 
synthesized compound1 and importantly, validated the successful biosynthetic 
production of its two TDP-4-keto-3-amino sugar precursors. In summary, these data 
indicate that the double N-oxidation catalyzed by the nitrososynthase ORF36 improves 
with substrates more closely related to TDP-L-epivancosamine and only a single 
oxidation step to a hydroxylamine occurs for the TDP-3-amino-4-keto sugar precursors. 
The oxidation of the C-4 O-methylated congener of TDP-L-epivancosamine remains to be 
investigated to determine whether this additional methyl group has any effect on the 
oxidation activity of ORF36. However, the isolation of everninomicin variants from M. 
carbonacea var. africana with both O-methyl and hydroxyl functionality in their 
corresponding nitrosugar moieties20, suggests that O-methyl substitution at this position 
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is not essential for nitrososynthase reactivity and may occur prior or subsequent to 
amine oxidation reactions.20 
 
18O2 incorporation in the ORF36 oxidation reaction. 
To determine whether the incorporation of the oxygen atom into the amino 
sugar substrate upon ORF36 activity with TDP-L-epivancosamine comes from molecular 
oxygen as opposed to oxygen from H2O, we performed the ORF36 oxidation reaction 
under 18O2.  The incorporation of molecular oxygen into the substrate would also 
support the flavin-dependent monooxygenase catalysis. To provide a control reaction, 
the same previous ORF36 assay with TDP-L-epivancosamine under 16O2 was repeated. 
Reactions contained the same concentrations of NADPH, FAD, flavin reductase, and 
ORF36 were incubated with catalytic excess of catalase21 under atmosphere of either 
18O2 or 
16O2.  As shown in figure III-3, HPLC-MS analysis showed single oxygen atom 
incorporation corresponding to the hydroxylamine intermediate (m/z = 560) and the 
nitroso product (m/z = 558), which demonstrated enrichment of the +2 m/z shift at 86% 
and 87% incorporation, respectively. 
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Figure III-3. The 
18
O2 incorporation studies of ORF36 oxidation reaction. (A) Summary of proposed 
species observed in the 
18
O2 incorporation experiments. (B-D) 
18
O2 incorporation with ORF36 and TDP-L-
epivancosamine incubated with 
16
O2 (green) and 
18
O2 (red). Masses shown under structures correspond 
to unlabeled species. HPLC-MS and MS/MS data were collected at a 15 min reaction time, when the 
hydroxylamine intermediate was most abundant. (B) TDP-L-epivancosamine (m/z 544 and tR = 4.5 min). 
(C) Hydroxylamine (m/z 560, and tR = 5.3 min). (D) Peaks at tR values of 7-9 min are proposed to 
correspond to the nitroso compound (tR = 8 min) and an additional oxidation product at m/z 576 (tR = 
7.8 min). This new mass has a retention time distinct from that of the nitroso sugar, and on the basis of 
MS/MS analysis, the additional mass of the m/z 576 ion is constrained to the pyranose ring. One 
possible structure is the 3-hydroxylamino-4-keto sugar, which is detected as a hydrate under ESI 
conditions. MS/MS analysis supports this hypothesis in that the labeled ion at m/z 578 readily 
fragments to an ion at m/z 560.09, and this fragmentation pattern is identical to the reaction product of 
the TDP-L-3-amino-4-keto sugar shifted by 2 mass units. This figure is taken from reference 14 in which 
the author of this document is a coauthor.  
 
In addition to confirming the incorporation of molecular oxygen into the 
expected oxidation products, these experiments also showed oxygen incorporation for 
additional reaction products. We observed a +2 m/z shift in what we have previously 
assigned to be the electrospray induced hydrate of the TDP-nitroso sugar (M + H2O, m/z 
= 576 ).1 However, the single incorporation of oxygen into this species and the lack of 
demonstrable back-exchange of labeled nitroso with H2O rule out the proposed 
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dihydroxylamino species. Closer examination of the HPLC/MS chromatograms indicated 
that within the broad peak encompassing this region, the nitrososugar (m/z 558), and 
the compound at m/z = 576 possess different retention times (8.8 and 7.8 min 
respectively). Both compounds contain fragmentation peaks diagnostic of a TDP-sugar 
including the loss of TDP (m/z = 401) and TMP (m/z = 321) but the unknown m/z 576 
compound demonstrated an additional major fragment at 558, indicating loss of water. 
Further characterization of the compound at m/z 576 was impeded by the lack of the 
availability of enough quantities and the inherent storage stability. However, The 
MS/MS analysis demonstrated that the oxidation is constrained to the pyranose ring, 
and considering the likelihood that the oxidation is occurring on the C-3/4 heteroatoms, 
we proposed that the m/z 576 peak corresponds to a product oxidized at C-4, likely the 
C-4 ketone. Consistent with that, this putative structure shares similar retention time 
and fragmentation pattern with the hydroxylamino product generated from the 
oxidation of the substrate analog TDP-L-3-amino-4-keto sugar (Figure III-2). It should be 
noted however, that other structures are possible, including a possible electrocyclic 
rearrangement of the hydroxyketone (not shown).22 Further structural elucidation of 
these oxidation products via chemical derivatization is discussed in chapter IV which 
revealed a surprising outcome. 
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X-ray crystal structure of ORF36 
In collaboration with Prof. Tina Iverson’s research group, Dr. Jessica Vey was able 
to crystallize and determine the structure of the ORF36 enzyme.14 The polyalanine 
model of human short-branched chain acyl-CoA dehydrogenase (PDB 2JIF)23 was used as 
the search model to determine the structure to a 3.15 Å resolution by molecular 
replacement (Figure III-4). ORF36 formed a tetramer with 3,500 Å2 of surface area 
buried per monomer. Size exclusion chromatography on a Superdex S-200 column 
confirmed the tetrameric structure of ORF36 in solution. The monomers of ORF36 adopt 
a three-domain fold with the N- and C-terminal helical domains separated by a β-sheet 
domain (Figure III-4B). The oligomerization interface of ORF36 is predominated by 
interactions between the adjacent C-terminal helical domains. 
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Figure III-4. Structure of ORF36. (A) The ORF36 tetramer is shown as a cartoon representation with a 
transparent surface, colored by domain.The N-terminal domains (residues 1-129) are colored gray, the 
central β-sheet domains (residues 130-235) green, and the C-terminal domains (residues 235-398) 
purple. (B) ORF36 monomer shown in cartoon representation with modeled FAD and TDP-L-
evernosamine shown as transparent sticks. Colors are as follows: yellow for FAD carbons, magenta for 
TDP-L-evernosamine carbons, red for oxygen, blue for nitrogen, and orange for phosphate. The view in 
panel B is rotated 45° about a vertical axis from the bottom monomer shown boxed in panel A. This 
figure is taken from reference 14 in which the author of this document is a coauthor.  
 
As this work was being prepared for publication early 2010, the structure of the 
nitrososynthase KijD3 was reported18 and appeared in the EMBL Dali search24 as the 
closest structural homolog. Both KijD3 and ORF36 share structural similarity with 
members of the acyl-CoA dehydrogenase superfamily25 which includes oxidases, 
dehydrogenases and flavin-containing monooxygenases.  The structural folds of ORF36 
and KijD3 are surprisingly closer to those of the dehydrogenases than the 
monooxygenase functional homologs which is in contrast with their functions as 
monooxygenases. One explanation for this could be that the monooxygenase activity of 
the nitrososynthases evolved independently from acyl-CoA dehydrogenases, while other 
class D monooxygenases and the acyl-CoA dehydrogenases underwent a divergent 
evolutionary route. 
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Modeling of FAD and TDP-L-epi-vancosamine in the active site 
Attempts to co-crystallize ORF36 with the flavin cofactors FAD and FMN each in 
their oxidized and reduced forms, as well as with the substrate TDP-L-epivancosamine 
were unsuccessful. None of these experiments resulted in the appearance of new 
electron density for the substrate or the flavin cofactor. Therefore, the FAD cofactor and 
the substrate TDP-L-epivancosamine were modeled into the active site of ORF36 using a 
combination of manual and automated methods. Ideal cofactor-substrate distances and 
geometry were predicted based on comparison with the co-structures of flaving-
containing monooxygenases in complex with their substrates.26-29 
The resulting predicted model suggests that the pre-formed pockets in the active 
site of ORF36 bind the isoalloxazine ring of the flavin cofactor and the TDP moiety of 
TDP-L-epivancosamine.  Residues in the vicinity of the predicted isoalloxazine ring 
pocket, particularly at loops L3, L5 and L9, are conserved in nitrosynthases and are 
similar to those in acyl-CoA dehydrogenases and flavin-containing monooxygenases. In 
contrast, the adenine nucleotide moiety of the flavin cofactor in this predicted model is 
in a region in the active site where the loops are in an open conformation.   Loop 7 in 
both dehydrogenases and flavin-containing monooxygenases, which forms specific 
contacts with flavin, is shorter in enzymes that preferentially bind FAD and longer in 
enzymes that preferentially bind FMN, and is known to undergo a conformational 
change upon flavin binding to facilitate contacts with the nucleotide moiety. This loop is 
similar to those found in acyl-CoA dehydrogenase superfamily that utilizes FAD as their 
flavin cofactor. This is supported by the observation that the activity of ORF36 is 
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significantly improved with the FAD cofactor as compared to that with FMN. In this 
ORF36 structure, loop L7 adopts a conformation that likely will undergo adjustment 
upon flavin binding. 
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Figure III-5. Active site loops. The loops that form the active site are as follows:  the loops between α3 
and α4 (loop L1; residues 106 – 109), β1 and β2 (loop L2; residues 134-142), β3 and β4 (loop L3, residues 
158-164), β4 and β5 (loop L4; residues 178-180), β6 and β7 (loop L5; residues 201-213), β9 and α6 (loop 
L6; residues 248-253), α6’ and α7’ (where the ’ indicates this is from an adjacent monomer; loop L7; 
residues 272-280), α7 and α8 (loop L8; residues 310-317), α8’ and α9’ (loop L9, residues 351-353), α9 
and α10, (loop L10; residues 375-379) and at the C-terminus (loop L11; residues 390-412). (A) A ribbon 
diagram of ORF36 shown with modeled flavin (yellow carbons) and TDP-L-evernosamine (magenta 
carbons) as sticks. Active site loops L3, L5, L7, and L9, are predicted to interact with flavin and are 
colored orange, active site loops L1, L4, L6, L8, and L11 are predicted to interact with substrate and are 
colored purple, and active site loops L2 and L10 are predicted to interact with both substrate and 
cofactor and are colored teal. (B) A ribbon diagram of human short branched-chain acyl Co-A 
dehydrogenase (PDB entry 2JIF) 
30
, highlighting loops L1 to L11 colored are colored as in (A). (C) A 
ribbon diagram of A. baumannii 4-hydroxyphenylacetate monooxygenase (PDB entry 2JBT) 
31 
highlighting loops L1 to L11 colored as in (A). (D) Stereoview of the ORF36 loop L10 containing a tandem 
cis-peptide. Loop L10 is shown in sticks with teal carbons. The Q376-P377 and P377-Y378 bonds both 
adopt a cis conformation. Modeled flavin and substrate are displayed as in (A). This figure is taken from 
reference 14 in which the author of this document is a coauthor.  
 
Description of the active site 
The predicted active site of ORF36 contains amino acid residues mainly from the 
central β-sheet domain and the N-terminal helical domain, but also includes residues 
from the C-terminal domain of an adjacent monomer.25 The base of the active site cleft 
is formed along helix α4. Flavin binding is predicted to be mediated by interactions with 
residues in α4, β1, α6 and α8, whereas substrate binding presumably occurs via 
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interactions with residues in α4 and α6-α8 helices. Additionally, loops L1-L11 
surrounding the active site likely play a role in substrate binding and catalysis.  Loops L1, 
L2, L4, L5, L6, L7, L8 and L11 differ in structure compared to their counterparts in the 
aforementioned structural homologs of nitrososynthases, suggesting that they likely 
play an important role in conferring substrate and cofactor specificity. 
The active sites of both ORF36 and KijD3 measure 30 Å wide by 20 Å deep and 
appear to be solvent exposed. This is in contrast to the active sites in flavin-containing 
monooxygenases and acyl-CoA dehydrogenases. This unusually large pocket results 
from the open conformations of loops L1, L2, L4, L6, L7, and L11 in ORF36 and KijD3, 
which is unlike the more compact conformations of their counterparts in the acyl-CoA 
dehydrogenases and flavin-containing monooxygenases. Most of these loops are known 
to have interactions with the substrate in the acyl-CoA dehydrogenase superfamily, 
suggesting that significant main chain conformational changes may occur upon 
substrate binding. Of note, loop L10 located on the floor of the active site cleft in ORF36 
likely contains tandem cis-peptide bonds between Gln 376 and Pro 377 and between 
Pro377 and Tyr 378. Although the assignment of cis-peptide bond is speculative at this 
resolution, modeling the loop with trans-peptide bonds or with only a single cis-proline 
resulted in disallowed Ramachandran angles for Tyr 378 and poor agreement of the 
main chain with the electron density. This assignment is also supported with the 
observation that KijD3, with its L10 sequence identical to that of ORF36, contains 
tandem cis-peptide bonds in this location.18 
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The crystallographic temperature factors of residues in the loops surrounding 
the active site in both ORF36 and KijD3 are significantly higher when compared to 
residues in the remainder of the protein.  Temperature factors, also known as atomic 
displacement parameters or B-factors, can reflect the thermal motion of atoms and hint 
at regions of increased relative mobility in a given structure. 
 
Discussion 
 
Substrate preference of ORF36 
The nitrososynthase activity of ORF36 with TDP-L-epi-vancosamine confirms that 
this aminosugar is preferred over its 4-ketosugar upstream congeners. Moreover, the O-
methylation of the C4 hydroxyl group of TDP-L-epivancosamine was shown not to be 
necessary for the nitrososynthase activity. This was an expected outcome, because a 
variant of everninomicin lacking the C4-O methylation in its nitrosugar moiety was also 
isolated from M. carbonacea var. africana.20 The single oxidation of the TDP 4-keto 
sugar substrates suggests that nitrososynthases in the biosynthesis of other nitrosugar-
containing natural products may act on closely related precursors not necessarily 
identical to TDP-L-eivancosamine. The retention times of the oxidation products from 
the 4-keto aminosugar substrates matches that of the nitroso sugar produced from the 
activity of ORF36 with TDP-L-epivancosamine. This led us to propose a shunt reaction 
product, the C4 ketone, in which the 4-hydroxy position of TDP-L-epivancosamine is 
oxidized perhaps via dehydrogenation or hydroperoxylation of the C4 hydroxyl to the 
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ketone oxidation state. Other oxidation possibilities may also exist. Preliminary 
experiments of the ORF36 activity with the authentic substrate TDP-evernosamine, 
which is protected by O-methylation at C4, showed the production of only the nitroso 
sugar with no additional oxidation products. The proposed oxidation of the C4 position 
of TDP-L-epivancosamine upon ORF36 activity is intriguing and further experimentation 
should be performed to validate the identity of the proposed structures. Chapter IV 
details some chemical derivatization experiments and HPLC/MS analysis of the 
derivatized oxidation products of the nitrososynthase activity with TDP-L-
epivancosamine which reveals a surprising outcome. 
 
Structural comparison of ORF36 and KijD3 
The overall structure of ORF3614 matches that of its KijD318 homolog from the 
kijanimicin biosynthetic pathway with a root-mean-square deviation of 0.76 Å between 
the Cα atoms of the tetramers of the two proteins. The main differences in both 
sequence and structure between these two homologs are found in the regions that map 
to the active site cleft, and may be related to differences in function and substrate 
binding. Of note, variations in the interface of the predicted isoalloxazine and the TDP 
binding sites may account for substrate preference. The TDP and the isoalloxazine 
binding pockets themselves are almost completely conserved in both enzymes. The 
major structural variations between ORF36 and KijD3 are apparent in the active site 
loops   L2, L4 and L6 located within the central β-sheet domain, and L7 and L8 of the C-
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terminal domain. The high crystallographic temperature factors of these regions in both 
enzymes may reflect flexibility that facilitates movements of the substrate or the 
cofactor upon catalysis. 
The active site of both nitrosoynthases ORF36 and KijD3 are relatively large and 
highly solvent accessible with their loops adopting open conformations. In comparison 
with structures of the acyl-coA dehydrogenases and class D flavin-containing 
monooxygenases, exclusion of water from the active site is presumably facilitated by 
conformational changes of loops L2, L4, L6, L7, L8 and L11. The active site residues have 
elevated temperature factors compared to the remainder of the protein likely 
accounting for substrate and cofactor mobility. Additionally, both enzymes possess a 
tandem cis-peptide bond within the active site loop L10 which likely undergoes 
isomerization initiating a conformational change to facilitate catalysis. These 
observations suggest that the active site loops may undergo significant conformational 
changes following cofactor and substrate binding. Conformational adjustments upon 
substrate binding are known for many enzymes30-31, which suggest that the open active 
site architecture of both ORF3614 and KijD318 maybe be physiologically relevant. The 
open loops in these enzymes may facilitate entry of the relatively large TDP sugar 
substrates, and the FAD cofactor. While further experiments are required to examine 
this possibility, this conformational variability in the active site may be necessary to 
prevent unwanted side reactions or nonproductive FAD cycling in the absence of 
substrate. 
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Proposed minimal mechanism of ORF36 
Our biochemical characterization experiments outlined in this work confirmed 
the previously proposed monooxygenase activity of the nitrososynthase ORF36. The 
HPLC-MS analysis of ORF36 activity suggests that the enzyme first oxidizes TDP-L-
epivancosamine to the hydroxylamine intermediate which undergoes a second flavin-
dependent N-oxidation step to yield the nitroso sugar. These two oxidation steps result 
in single incorporation of oxygen into in the nitrososugar product evidenced by the 
results from performing the ORF36 oxidation reaction under 18O2. Based on these 
observations, and with typical falvin-dependent monooxygenase mechanisms taken into 
consideration, we propose that ORF36 oxidation activity is mediated by flavin-C4a-
hydroperoxide acting as an electrophile in a nucleophilic substitution reaction.32-33 
Under this monooxygenation scenario, ORF36 likely first binds reduced flavin, 
generated by an external flavin reductase which readily reacts with molecular oxygen to 
form the oxidative electrophile flavin-C4a-hydroperoxide. This series of transformations 
are typical for flavin-dependent monooxygenases.34 Subsequently, the aminosugar 
substrate binds and undergoes oxidation to form the hydroxylamino intermediate while 
the flavin cofactor is transformed to the C4a-hydroxyflavin which upon dehydration 
regenerates the diffusible oxidized flavin to be released along with the hydroxylamine. A 
similar second N-oxidation step followed by dehydration generates the nitroso sugar 
product. Alternatively, the nitroso sugar could be generated via a dehydrogenase 
mechanism similar to that catalyzed by the homologous acyl-CoA dehydrogenase. We 
performed the ORF36 oxidation reaction with TDP-L-epivancosamine under limited 
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concentration of NADPH (0.4 mM) and observed the formation of only the 
hydroxylamine intermediate suggesting that the second oxidation step requires reduced 
flavin. Therefore, we favor a monooxygenase activity that involves iterative electrophilic 
oxygenation followed by dehydration over the dehydrogenase mechanism. In support of 
molecular oxygen participation in catalysis, incorporation of single 18O atom into the 
final product could be only observed when the oxidation reaction was performed under 
18O2, but not H2
18O. 
 
Conclusions 
This work provided important biochemical characterization of the new flavin-
dependent nitrososynthase ORF36 which catalyzes the N-oxidation of the aminosugar 
TDP-L-epivancosamine to its corresponding nitrososugar. We propose that the 
tetrameric enzyme undergoes conformational changes upon binding of the flavin 
cofactor and the substrate to facilitate the monooxygenation catalysis. The 
nitrososynthase enzyme represents a new class of flavin-dependent monooxygenases 
with an acyl-CoA dehydrogenase fold. The surprising contrast in the function of the 
nitrososynthase compared to its structural closest homologs suggests that 
nitrososynthases have functionally evolved divergently from acyl-CoA dehydrogenases. 
This could have implications on the growing number of enzymes annotated as acyl-CoA 
dehydrogenase-like enzymes, while they possibly perform different oxidation reactions. 
Future investigations of the activity of ORF36 with other aminosugar substrates such as 
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the authentic C4 O-methylated TDP-L-evernosamine will lead to a better understanding 
of the molecular determinants controlling selectivity and catalysis by this new class of 
enzymes. The biochemical characterization experiments provided in this work allowed 
the proposal of reasonable minimal mechanism which sets the stage for future 
mechanistic and structural studies. 
 
Materials and methods 
 
Overexpression and purification of enzymes. ORF36 from M. carbonacea var. 
africana14, EvaA–E from Amycolatopsis orientalis13, and RfbB from Salmonella enterica 
(strain LT2)35-36 were purified from freshly transformed E. coli BL21(DE3) by nickel 
affinity chromatography as previously described with the exception of EvaE, which was 
isolated as an insoluble preparation. EvaE preparations were generated from 3 L 
induced cultures, which were disrupted via a French pressure cell. The insoluble fraction 
was isolated by centrifugation and washed with 20 mM Tris-HCl, pH 7.5, resuspended in 
10 mL, 20 mM Tris-HCl, pH 7.5, 5% glycerol, and stored at -80 °C prior to use. 
Preparation of TDP-6-deoxy-4-keto-D-glucose. Reactions (1 mL) containing 8 
mM thymidine 5’-diphosphate-glucose disodium salt (4.5 mg), 50 mM Tris-HCl (pH 8.0), 
4 mM NADP+, and 160 µM RfbB were incubated at 24 °C for two hours. Proteins were 
removed by 10K molecular weight cutoff filtration (Centricon, Millipore Corp.) and the 
product was purified via SAX-HPLC (see below) followed by lyophilization. The final yield 
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was 4.0 mg of TDP-6-deoxy-4-keto-D-glucose (88% yield). TDP-6-deoxy-4-keto-D-glucose 
was analyzed by ESI-LC/MS, which determined the m/z to be 563.20 ([M-H + H2O]-, 
calculated for C16H25N2O16P2 is 563.07). 
Preparation of other TDP-sugars substrates and intermediates. Other TDP-
sugars were biochemically synthesized from TDP-6-deoxy-4-keto-D-glucose using 
purified enzyme preparations and the general procedures outlined by Chen et. al.13 with 
the following modifications. Briefly, thimidine-5’-diphosphate-3-amino-2,3,6-trideoxy-3-
C-methyl-D-erythrohexopyranos-4-ulose (the TDP-4-keto-3-amino D-sugar), was 
synthesized via tandem reaction with EvaA, EvaB and EvaC and purified as described 
below in a 36% overall yield for three steps. ESI-LC mass spectra yielded the m/z of 
560.27 ([M-H + H2O]
-, calculated for C17H28N3O14P2 is 560.10). The substrate thymidine-
5-diphospho-3-amino-2,3,6-trideoxy-3-C-methyl-L-arabinohexose (TDP-epivancosamine) 
was generated from the TDP-4-keto-3-amino D-sugar (1 mM) in a 1-mL reaction 
containing 100 mM Tris-HCl (pH 7.5), 5 mM NADPH, 20 µM EvaD and 50 µL of the 
resuspended EvaE pellet. The reaction was incubated at 24 °C for 2 h, proteins and cell 
debris were removed using a 10K centrifugal filter (Centricon), and the product was 
purified by SAX-HPLC (described below) followed by lyophilization which resulted in 300 
µg (55% yield) of TDP-L-epivancosamine. ESI-LC MS confirmed the mass of TDP-L-
epivancosamine ([M-H]- calculated for C17H28N3O13P2 is 544.11, found 544.27). 
Purification of TDP-sugars. Preparative enzymatic reaction progress was 
followed via HPLC using a series 600 Waters HPLC system with a Waters 2996 diode 
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array detector. Analytical separations were performed on an Adsorbosphere strong 
anion exchange (SAX) column (5 mm, 4.6 x 20 mm, Alltech Associates) and a linear 
gradient of 50 to 500 mM NH4HCO2, pH 3.5, at 1 mL/min for 45 min. Preparative HPLC 
separations were performed using a semi-preparative Adsorbosphere SAX column (5 
µm, 22 x 250 mm) using a similar protocol, but at 10 mL/min. The pH of the fractions 
containing TDP-chromophores (267 nm) were immediately adjusted to ~7 with 1 M 
NH4OH and fractions containing reaction product were pooled, lyophilized and stored at 
-80 °C until assayed. Resuspended compound concentrations were determined by 
measuring the absorbance at 267 nm using a Nanodrop spectrophotometer (Thermo, 
Inc.) and comparison to a standard curve of dTDP. 
ORF36 enzymatic reactions with the aminosugar substrates. Reactions of 
ORF36 with the TDP-4-keto-3-amino D-sugar and TDP-L-epivancosamine were performed 
in a total volume of 50 μL containing 30 μM of the corresponding substrates with 30 μM 
FAD, 1 U/mL catalase, 0.05 U flavin reductase, and 2.0 mM NADPH. The  TDP-4-keto-3-
amino L-sugar was generated in situ by including 20 µM EvaD in the reaction with its D-
sugar precursor. All reactions were initiated by addition of 12 µM ORF36 and 10 μL 
samples were withdrawn at increasing time points (0 - 120 min) and were quenched 
with 10 μL of acetone and stored at -80 °C until analyzed by LC-ESI/MS. Control assays 
were performed omitting ORF36, FAD, or NADPH. 
18O2-incorporation assays. Reactions with 
18O2 gas were performed in a 5 mL 
round bottom flask fitted with a rubber septum and a balloon (~5 mL, connected via a 
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syringe needle). The reaction vessel at 4 °C was connected via stainless steel cannula to 
a closed gas cylinder (Cambridge Isotope Laboratories) containing 1 L, 22 psi of 18O2 that 
was also fitted with a rubber septum. A freshly prepared solution (200 µL) containing 20 
mM Tris-HCl, pH 7.5, 30 μM FAD, 1 U/mL catalase, 0.05 U/mL flavin reductase, 2.0 mM 
NADPH, and 0.5 mg/mL ORF36 was introduced into the flask and the entire reaction 
system was degassed in vacuo (25 - 50 mm Hg) for 20 minutes. The 18O2 cylinder was 
opened to release sufficient 18O2 to fill the flask and the small balloon with ~5-10 mL of 
gas. Reactions were initiated by the addition of 30 µM of vacuum degassed TDP-L-epi-
vancosamine via a gas-tight syringe. Reactions were followed for 2 h at 30 °C by 
withdrawing 25 µL aliquots via syringe at increasing time points, quenching via addition 
of 25 µL acetone and storing samples at -80 °C until analyzed by LC-ESI/MS as described 
below. 
 
LC-ESI/MS method for ORF36 Substrates.The oxidation of ORF36 substrates was 
analyzed using Agilent 1100 HPLC system (Agilent, Palo Alto, CA) with a LCQ Quantum 
Decca XP ion trap mass analyzer (ThermoFinnigan, San Jose, CA) equipped with an API 
electrospray ionization source fitted with a 50 μm I.D. deactivated fused silica capillary. 
Injections of 10 μl were separated using a Hypercarb column (3 × 50 mm, Thermo Inc). 
Mobile phases were: (A) H2O with 50 mM NH4CH3COO
- and 0.1% (v/v) diethylamine and 
(B) H2O/acetonitrile (5:95) with 50 mM NH4CH3COO
-  and 0.1% (v/v) diethylamine. 
Gradient conditions were as follows: 0-5 min, B = 15%; 5-15 min, linear gradient to 35% 
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B; 15 to 16 min, linear gradient to 100% B; 16 to 21 min, B = 100%; 21 to 22 min, linear 
gradient to 15% B; 22-30 min, B = 15%. The flow rate was maintained at 0.3 ml/min. The 
mass spectrometer was operated in both the negative ion and full scan profile modes 
and the electrospray needle was maintained at 3,400 V. The ion transfer tube was 
operated at -47.50 V and 275°C. The tube lens voltage was set to -46 V. The collision 
energy for all product ion scans was set at 30%. For TDP-L-epi-vancosamine 10, full 
product and ion scans were set as follows: 544→155-548; 558→155-560; 560→155-562. 
For the assays with the 3-amin-4-keto sugars, the scans were set as follows: 542→155-
548; 560→155-562; 558→155-560. Data were acquired in profile mode. The following 
optimized parameters were used for the detection: N2 sheath gas 46 psi; N2 auxiliary gas 
13 psi; spray voltage 3.4 kV. 
Crystallization of ORF36. Initial crystallization conditions for ORF36 were 
identified by sparse matrix screening and were improved using diffraction-based 
feedback on the Life Sciences Collaborative Access Team (LS-CAT) beamlines 21-ID-D, 
21-ID-F, and 21-ID-G at the Advanced Photon Source (APS), and beamline 9-1 at 
Stanford Synchrotron Radiation Lightsource (SSRL). Optimized crystals of ORF36 were 
grown using the hanging drop vapor diffusion technique at 277 K from drops containing 
1 µL protein solution (7 mg/mL ORF36 in 20 mM Tris.HCl, 5% glycerol, 1 mM DTT, pH 
7.5) and 1 µL crystallization solution (0.1 M Tris-HCl pH 8.5, 0.2 M MgCl2, 10% 
polyethylene glycol 4000), equilibrated against 1 mL crystallization solution. Crystals 
belonging to the hexagonal space group P65 reached a maximal size of 0.1 mm x 0.1 mm 
x 0.4 mm in 5-6 days. The volume of the unit cell was consistent with a tetramer in the 
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asymmetric unit and 53% solvent content. Crystals were cryoprotected by equilibration 
in crystallization solution supplemented with 20% glycerol or 20% ethylene glycol and 
cryo-cooled in liquid nitrogen prior to data collection. 
Native data set 1 was collected at 100 K at the beamline 21-ID-D of the Advanced 
Photon Source using a Rayonix MX 225 detector. Native data set 2 was collected at 100 
K on beamline 9-2 at SSRL using a MarUSA MarMosaic-325 CCD detector. Data 
integration and scaling were performed with the HKL2000 suite of programs. 
Structure determination and refinement. The structure of ORF36 was 
determined by molecular replacement in Phaser37 using a polyalanine version of the 
human short-branched chain acyl-CoA dehydrogenase tetramer as the search model 
(PDB entry 2JIF23 (35), 25% sequence identity). Molecular replacement was only 
successful with the Native data set 1. The molecular replacement solution was 
transferred into the higher-resolution Native data set 2 and refined using alternating 
rounds of manual model building in XtalView38 and refinement in CNS39 with strict non-
crystallographic symmetry (NCS) constraints. Once the R¬cryst reached 26%, each chain 
was examined for main chain differences, which were observed within the central β-
domain between the ORF36 monomers. As a result, during the final four cycles of 
refinement, each monomer was refined with NCS restraints applied to the N- and C-
terminal domains, but deviations from NCS were allowed in the central β-domain. 
The final model of ORF36 comprises residues 1 to 395 (of 412 total residues), 
with several breaks observed in chains B, C, and D. In chain B, electron density for 
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residues 143-151, 177-184, and 229-235 is not observed; in chain C, electron density for 
residues 144-156, 176-182, 218-221 and 235 is not observed; in chain D electron density 
for residues 226-227 and 316 is not observed. The test set of reflections for the Rfree 
consisted of 9.1% of the data, totaling 2816 reflections. The final model has an Rcryst of 
24.2%, an Rfree of 28.1%, 88.5% of residues in the most favored regions of the 
Ramachandran diagram, 10.9% in the additionally allowed regions, 0.6% in the 
generously allowed regions, and 0.0% in the disallowed regions. Figures III-4 was 
prepared with PyMOL.40 Figure III-5 was prepared using MOLSCRIPT41 and Raster3D.42 
Modeling of substrate and cofactor. FAD was modeled into the active site by 
superpositioning the ORF36 structure with that of human short-branched chain acyl-CoA 
dehydrogenase (PDB entry 2JIF23) and using the position of bound FAD from 2JIF as a 
starting point. Attempts to improve the position of FAD using the molecular docking 
program Molecular Operating Environment (MOE, Chemical Computing Group, 
Montreal, Canada) did not result in a solution that both alleviated steric clashes 
between the FAD and protein and retained a reasonable position for the isoalloxazine 
ring. 
A model for TDP-L-evernosamine was constructed by manual combination of 
deoxythymidine diphosphate (ligand name TYD) and the epi-vancosaminyl derivative of 
vancomycin (ligand name VAX), both available via the HIC-Up server.43 The TDP-L-
evernosamine was manually positioned within the active site such that the amino sugar 
was within 5.5 Å of the expected position of the C4a of the isoalloxazine ring, but the 
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location of the TDP varied. The docking algorithm in MOE was used to improve each 
manual starting point. Docking was performed using a radius of 10 Å around the initial 
position of the ligand, the triangle matcher algorithm for placement, London dG 
rescoring, and force field refinement. Between 30 and 100 positions were retained from 
each trial and validated manually by evaluating the orientation of the sugar moiety in 
the active site, and the distance of the amino group from the expected position of C4a 
of the isoalloxazine ring. The optimized position for TDP-L-evernosamine had a location 
of the TDP similar to that experimentally observed for the ordered dTDP moiety of 
dTDP-phenol in complex with the nitrososynthase KijD3.18 
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Chapter IV 
 
RETRO-ALDOL ACTIVITY OF THE NITROSOSYNTHASE DNMZ 
 
 
Introduction 
 
The anthracycline antibiotics and anticancer agents are very important class of 
aromatic microbial polyketides.1-3 These red compounds are produced by some strains 
of Streptomyces, and about one quarter of them was found in so-called rare 
actinomycetes.4 Anthracyclines are diversified structurally through modifications in their 
tetracyclic polyketide core and a wide array of attached deoxysugar appendages.  The 
high interest in studying anthracyclines arose from their remarkable pharmaceutical 
properties especially their potent antitumor activities. Consequently, they have been 
some of the most intensively studied natural products over the past 50 years.5 
Daunorubicin and doxorubicin produced by Streptomyces peucetius are among 
the first isolated anthracyclines (Figure IV-1).6-7  Clinically, they are useful against several 
types of cancer especially solid tumors that are normally resistant to most types of 
chemotherapy. However, the use of anthracyclines for cancer treatment is usually 
accompanied by undesired side effects such as dose-related cardiotoxicity.8 Therefore, 
researchers have been interested in developing synthetic and other biogenic 
anthracycline derivatives to achieve improved pharmacological properties. To that end, 
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many efforts have been made to diversify the structures of anthracyclines with the aim 
of creating a wider spectrum of activities and reduced toxicity.9-14 
 
 
Figure IV-1. Chemical structure of known anthracyclines 
 
The tetracyclic polyketide core in anthracyclines is typically assembled from 
acetyl units in the form of malonyl- CoA by an iterative, type II polyketide synthase 
followed by aromatase, cyclase and tailoring enzymes.15-17 This yields the basic 
tetracyclic structure which undergoes subsequent enzymatic modification steps. The 
biosynthesis of most anthracyclines starts with the incorporation of a propinyl starter 
unit from propinyl-CoA, catalyzed by a ketoreductase and a thioesterase. In 
daunorubicin, a precursor for baumycin, the minimal PKS proteins that catalyze the 
formation of the long chain polyketide, are an acyl carrier protein (ACP), ketosynthase 
(KS) and a malonyl-CoA:ACP acyltransferase (MAT).18 The polyketide chain is converted 
to 12-deoxyalkalonic acid catalyzed by the dps gene cluster which includes DpsE, an 
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NADPH dependent 9-ketoreductase, and cyclases DpsF and DpsY that catalyze the 
formation of ring D and C, respectively.19 The subsequent polyketide modifications are 
catalyzed by the dnr gene cluster which includes C-12 oxygenase, a SAM dependent 
alkalonic acid methyltransferase, ring A cyclase, C-7 ketoreductase, and a C-11 
hydroxylase.20 This series of polyketide modifications yields ɛ-rhodomycinone (Figure IV-
1), the precursor for doxorubicin and daunorubicin. 
Perhaps the most important chemical modification of the anthracycline aglycone 
core is glycosylation at one or several positions. It has been shown that the deoxysugar 
moieties are required for the antimicrobial and antitumor activities.21 The deoxysugar 
moieties are usually attached at position C-7 and/or C-10 of the aglycone core by a 
variety of glycosyltransferases.22-24  In daunorubicin, the deoxysugar L-daunosamine is 
attached at C-7 of the tetracyclic polyketide.  The biosynthesis of the L-daunosamine 
sugar has been studied via molecular genetics, which identified six biosynthetic genes 
responsible for the formation of its TDP-activated derivative starting from glucose-1-
phosphate.25 The presence of additional deoxysugar genes in the daunorubicin gene 
cluster such as dnrh which encodes a glycosyltransferase, indicated that daunorubicin is 
a precursor for further glycoslated downstream derivatives. Daunorubicin was shown to 
be a precursor of baumycin, which includes a non-sugar acetal moity attached at C-4 
hydroxyl of the daunosamine sugar.26 Other baumycin-like compounds such as the 
angiostatic agent TAN-1120 (Figure IV-1) have also been isolated from Streptomyces 
peucetius.27 Besides dnrh, two more deoxysugar genes were found in the daunorubicin 
gene cluster: dnrx which encodes a SAM dependent C-3-methyltransferase, and dnmz 
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which encodes a flavin-dependent nitrososynthase homologous to ORF36 described in 
chapters II and III.28 
The DnmZ protein shares high sequence homology with the nitrososynthases 
ORF36, RubN8 and KijD3.29-30 For example, DnmZ25 shares 70% sequence similarity with 
ORF36 (59% Identity). This strongly suggests that DnmZ catalyzes a flavin-dependent 
deoxyaminosugar oxidation. Given the fact that there are no N-oxidized deoxysugar 
moieties in any of the anthracycline derivatives produced by Streptomyces peucetius 
isolated to date, the role of DnmZ in the biosynthesis of these compounds is seemingly 
puzzling.  However, one scenario can be envisioned in which DnmZ catalyzes a 
deoxyaminosugar oxidation similar to that carried out by its nitrososynthase 
homologues, whereby the resulting sugar undergoes further enzymatic and/or chemical 
transformations either before or after glycoslation. 
Our investigations to elucidate the role of DnmZ in the biosynthesis of baumycin-
like anthracyclines from Streptomyces peucetius, aimed at providing biochemical 
evidence of its activity as a flavin-dependent nitrososynthase. Additionally, we were 
interested in investigating the fate of the N-oxidation product of DnmZ and the possible 
pathways for its further enzymatic or chemical modifications. 
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Results and discussion 
 
Proposed activity of DnmZ 
The biosynthesis of the non-sugar acetal moiety attached at the C4 hydroxyl of L-
daunosamine in baumycin (Figure IV-1) is not yet studied. Synthesis of its carbon 
skeleton and functionalities are hard to assign to known enzymatic transformations. 
One possibility is that this 7-carbon moiety originates from a deoxysugar precursor 
which undergoes enzymatic and/or chemical modifications involving a carbon-carbon 
bond cleavage. The presence of additional genes that encode for deoxysugar modifying 
enzymes in the anthracycline gene cluster of Streptomyces peucetius, is in support of 
this hypothesis.31 We proposed that the DnmZ enzyme could catalyze a flavin-
dependent N-oxidation of a TDP-aminosugar precursor to yield its nitroso congener 
given its high similarity with the nitrososynthases ORF36 and RubN8. The C-3 
methyltransferase DnrX28 is likely involved in the production of the TDP activated 
deoxyaminosugar substrate of the DnmZ enzyme. One biosynthetic pathway of this 
substrate could be proposed in which the SAM dependent methyltransferase DnrX 
activity follows the transamination by DnmJ forming the C-3 methylated TDP-sugar. This 
methylation step is not required for the biosynthesis of L-daunosamine25 and maybe a 
key requirement for subsequent deoxyaminosugar oxidation activity. This is consistent 
with the methylation at C-3 in the deoxynitrosugars L-evrnitrose, D-rubranose, and L-
kijanose biosynthesized via a nitrososynthase activity.32-34 The subsequent step to 
produce the DnmZ substrate could be carried out by a C-4 ketoreductase (possibly 
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DnmV) to yield TDP-L-epivancosamine, which was shown to be a substrate for the 
nitrososynthase homologue ORF36. Amine oxidation of this TDP-sugar by DnmZ could 
set the stage for further enzymatic and/or chemical transformations ultimately resulting 
in the formation of the 7-carbon acetal moiety in baumycin. 
Pillay and co-workers35 reported a chemical precedent in which a carbon-carbon 
bond cleavage of the norbornane 2-exo-nitroso-3-exo-hydroxybicyclo[2.2.1]heptane was 
observed upon reflux of this compound in methanol (Figure IV-2). It was shown that the 
cleavage results in the formation of an aldehyde at C3 and an oxime at C2 of the 
molecule. The authors clarified that the cis-C-2-nitroso-3-hydroxy configuration is 
required for the cleavage reaction because it facilitates the easy proton transfer from 
the hydroxyl group to the nitroso group. 
 
 
 
Figure IV-2. Carbon-carbon bond cleavage reaction of 2-exo-nitroso-3-exo-hydroxy norbornane. 
 
A similar scenario could be envisioned for the TDP linked C3-nitroso-C-4-hydroxy 
sugar product of DnmZ in which an enzyme mediated C3-C4 bond cleavage results in the 
formation of an aldehyde at C4 and an oxime at C3 (figure IV-3).  The nitroso congener 
of TDP-L-epivancosamine36 possesses the trans-configuration for the nitroso-hydroxy 
groups and a cleavage reaction in this case would likely be enzymatically catalyzed. If 
this proposed transformation is proven true, it would represent a retro-aldol activity of 
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the nitrososynthase DnmZ, a function not known for any falvin dependent 
monooxygenase characterized to date. 
 
 
 
Figure IV-3. Proposed pathway for the DnmZ monooxygenation activity and the subsequent cleavge and 
glycoslation activities. 
 
Activity of DnmZ as a nitrososynthase 
Given the high sequence homology of DnmZ with the characterized flavin-
dependent nitrososynthase ORF36, it is expected that both enzymes catalyze similar 
deoxysugar N-oxidation reaction. To confirm this, we amplified the dnmz gene from 
Streptomyces peucetius via the polymerase-chain reaction (PCR), cloned it into the 
NdeI/HindIII sites of pET28a expression vector, and transformed the resulting plasmid 
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into the BL21 DE3 E.coli bacterial strain via electroporation. Expression conditions for 
the protein were found to be similar to those previously described for its ORF36 and 
RubN8 homologues. The protein was purified by Ni-affinity chromatography and 
analyzed by SDS-PAGE (Figure IV-4). 
 
 
Figure IV-4. SDS-PAGE gel of Ni-affinity purified DnmZ 
 
We used the biogenic aminosugar TDP-L-epivancosamine as a substrate to assay 
the nitrososynthase activity of DnmZ and followed the same assay conditions performed 
for ORF36 oxidation reaction.  The HPLC-MS analysis of the DnmZ assay showed similar 
reaction profile as that of ORF36 ultimately yielding products with m/z 558 and 576 
previously identified as the nitrososugar congener and a shunt oxidation product 
respectively. 
According to our proposed retro-aldol activity of Dnmz, the C3-C4 bond cleavage 
would result in an aldehyde at C4 and an oxime at C3 of the TDP-3-nitro-4-hydroxy sugar 
(Figure IV-3). This TDP linked compound with terminal oxime and aldehyde groups has 
an m/z of 558 in the negative mode. Aldehydes are known to exist in their hydrated 
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form which is consistent with the compound appearing at m/z 576 previously proposed 
to be an oxidation shunt product. These two compounds elute at a very similar 
retention time suggesting that they exist in equilibrium. 
 
Hydrazone derivatization of the DnmZ oxidation product 
The proposed oxime-aldehyde product formed upon TDP-L-epivancosamine 
oxidation by DnmZ could be confirmed by a hydrazone derivatization at the aldehyde 
group (Scheme IV-2). Aldehydes are known to react with hydrazines to form their 
corresponding hydrazone derivatives.37 
 
 
Scheme IV-2. Hydrozone derivatization of the proposed oxime-aldehyde product. 
 
We performed this derivatization by incubating the completed DnmZ assay 
separately with three hydrazine compounds; phenyl hydrazine; 2-
bromophenylhydrazine; and 2-hydrazino-N,N,N-trimethyl-2-oxo-ethanaminium chloride, 
known as Girard’s T reagent (GirT).38 The incubation time for these reactions was 2h at 
room temperature and the mixtures were immediately analyzed by HPLC-MS. The GirT 
hydrazone derivative advantageously possesses the positively charged 
trimethylammonium group facilitating analysis in the positive mode unlike the phenyl- 
and the 2-bromophenyl hydrazone derivatives which were best analyzed in the negative 
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mode aided by deprotonation of their attached nucleotide phosphates. As shown in 
figure IV-5, HPLC-MS peaks at m/z’s corresponding to all of the expected three 
hydrazone derivatives were observed at different retention times.  The 
phenylhydrazone derivative was observed at 31.1 minutes matching the expected m/z 
of 648. The 2-bromophynlhydrazone derivative appeared at 34.4 minutes with m/z’s of 
726 and 728 at similar abundance corresponding to the bromine isotopic distribution.39 
Finally, the GirT hydrazone derivative was observed at 26.4 minutes with m/z of 673 in 
the positive mode. The observation of m/z’s matching these hydrozone conjugates is 
consistent with the proposed TDP-linked oxime-aldehyde product; however, further 
structure characterization is required to validate the identity of these conjugates. 
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Figure IV-5. HPLC-MS analysis of the DnmZ reaction and the hydrozone conjugates of the oxidation 
product. 
 
Tandem MS analysis of the hydrazone derivatives. 
To further confirm the identity of the three TDP-linked hydrazone derivatives, we 
performed a tandem MS fragmentation of their corresponding product ions. 
Fragmentation of the phenyl- and the 2-bromophenylhydrazone product ions at m/z’s 
648 and 728 respectively, resulted in the diagnostic fragment ion at m/z 401, 
corresponding to the TDP anion, and its dehydrated form at m/z 383 (Figure IV-6). The 
presence of these fragment ions, confirms the thymidine diphosphate linkage present in 
their deoxyaminosugar precursors. Another species with lower intensity at m/z 529 was 
observed from the fragmentation of the 2-bromophenylhydrazone product ion of m/z 
728 (Figure IV-6). This fragment corresponds to the loss of the 2-bromophenyl 
hydrazone moiety which supports the presence of the proposed TDP linked oxime. 
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Figure IV-6. Tandem LC-ESI-MS of the 2-bromophenyl hydrozone derivative 
 
Changing the fragmentation conditions for these two hydrazones in both the 
negative and the positive modes did not result in any additional observable fragment 
ions diagnostic of the hydrazone side of these derivatives. Therefore, we performed 
tandem MS fragmentation of the GirT hydrazone product ion of m/z 673 in the positive 
mode. The hydrazone side of this molecular ion is positively charged, and as expected its 
fragmentation produced several fragment ions that could be easily assigned to relevant 
structures. Of note were the fragments that represented to the loss of thymidine 
monophosphate (TMP) at m/z 351, and the loss of TDP at m/z 271 (Figure IV-7).   
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Another fragment was observed at m/z 170 which is a result of the cleavage of the 
acetal’s C-O bond as shown in Figure IV-7. 
 
 
 
Figure IV-7. Tandem LC-ESI-MS of the GirT hydrozone derivative 
 
Acid hydrolysis and HPLC-MS analysis of the Girard’s hydrazone derivative 
We aimed to obtain more structural evidence of the hydrazone conjugates by 
hydrolyzing these derivatives with 1 M HCl and analyzing the resulting mixture by HPLC-
MS. The acid hydrolysis of these acetal molecules would result in the formation of an 
alcohol on the hydrazone side and an aldehyde on the oxime side of the molecule 
(Figure IV-8). The TDP moiety is readily hydrolyzed upon acid treatment.  Since the 
 
 
134 
 
hydrazine is present in excess, the newly formed aldehyde species is expected to form a 
second hydrazone conjugate at the anomeric C1 of the original sugar. HPLC-MS analysis 
both in the negative and positive modes identified no molecular ions corresponding to 
the expected hydrolyzed fragments of the acid-treated phenyl- and 2-bromophenyl 
hydrazone derivatives. This is perhaps due to the lack of ionization of the small 
molecular weight hydrolysis products possessing neutral charge. However, the acid 
treatment of the positively charged GirT hydrazone derivative produced two species at 
m/z 188 and 215 corresponding to both the oxime and the alcohol hydrazone 
conjugates while the original GirT hydrozone disappeared (Figure IV-8). 
 
 
 
Figure IV-8. Acid hydrolysis of the (carboxymethyl)trimethylammonium hydrazone derivative (above), 
and LC-ESI-MS chromatograms of the hydrolyzed species (below). 
 
Further MS/MS analysis of these species showed fragment ions consistent with 
their structures (Figure IV-9). Of note, fragmentation of the hydrazone derivative at m/z 
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188 resulted in species corresponding to the loss of the trimethylammonium group at 
m/z 129; dehydration of the secondary alcohol at m/z 170, and the cleavage of the 
amide bond to yield a fragment ion with m/z 87. The oxime hydrazone derivative at m/z 
215 also showed a fragment corresponding to the loss of the   trimethylammonium 
group at m/z 156 as well as a fragment corresponding to the formation of the 
protonated trimethylammonium species at m/z 60. These tandem MS data strongly 
support the structure assignment of the original GirT hydrazone derivative and provide 
more evidence for the carbon-carbon bond cleavage of the TDP-attached nitrososugar 
product of DnmZ oxidation. 
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Figure IV-9. Tandem LC-ESI-MS spectra of the hydrolysis products of the  acid treated GirT hydrazone 
derivative. Fragmentation of the hydrazone at m/z 188 (above), and the hydrazone at m/z 215 (below). 
 
High resolution MS measurements of the hydrazone derivatives 
To further verify the identity of the hydrazone derivatives, we performed high 
resolution LC-ESI-MS measurements. Reaction mixtures of all three original hydrazone 
conjugates and the two formed upon acid treatment of the GirT hydrazone were 
 
 
137 
 
measured. As shown in Figure IV-10, mass accuracies of less than 2.70 ppm were 
confirmed for all of the hydrazone conjugates measured. Taken together, these high 
resolution mass measurements are consistent with the assigned structures of the TDP 
linked hydraznes and are in support of the proposed deoxysugar C-C bond cleavge 
mediated by DnmZ activity. 
 
 
Figure IV-10. High resolution mass measurements of the hydrazone derivatives. 
 
Conclusion 
In this work, we used the nitrososynthase Dnmz from Streptomyces peucetius to 
show that the formation of the previously uncharecterized acetal moiety in baumycin is 
derived from the cleavage of a carbon-carbon bond mediated by DnmZ N-oxidation of a 
TDP-deoxyaminosugar. This retro-aldol activity of DmnZ represents a new flavin-
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dependent monooxygenase function which is of great significance for elucidating the 
biosynthetic pathways of various natural products such as baumycin-like anthracyclines. 
This additional monooxygenase reactivity is also helpful in chemical synthesis and 
provides green biocatalysis for some difficult to perform retro-aldol reactions. Future 
investigations of this pathway should focus on elucidating the glycosylation 
requirements as well as the reduction steps of the oxime and aldehyde groups to 
ultimately form the alcohol functionalities. 
 
Materials and methods 
 
Bacterial strains, Plasmids and Materials. 
All reagents were obtained from Sigma-Aldrich Corporation and used without 
further purification unless otherwise noted. E. coli TOP10 and BL21 (DE3) competent 
cells were obtained from Invitrogen Inc. (Carlsbad, CA) and Novagen (Madison, WI), 
respectively. Restriction endonucleases and T4 DNA ligase were obtained from New 
England Biolabs (Ipswich, MA). The pET28a expression vector was purchased from 
Novagen Inc. Taqplus DNA polymerase was purchased from Stratagene Inc. (La Jolla, 
CA). 
 
Cloning and overexpression of dnmZ. 
The gene encoding DnmZ was amplified from the genomic DNA of Streptomyces 
peucetius17 using the following primers 5’- CATATGACAAAGCCATCTGTGCACG-3’ and 5’-
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AAGCTTTCATCGGCCCAACGCC- ACTT-3’ (NdeI and HindIII restriction enzyme sites 
underlined). PCR reactions were carried out using Taqplus DNA polymerase according to 
the manufacture’s protocol. Subcloning of dnmZ into the NdeI/HindIII sites of pET28a 
yielded recombinant plasmid pET28-ZN for expression as an N-terminal hexahistidine 
fusion protein. Plasmid pET28-ZN was transformed by electroporation into E. coli 
BL21(DE3) for heterologous expression of DnmZ. Cultures of E. coli BL21(DE3)/pET28-ZN 
were grown at 37°C to an OD600 of 0.6, at which point the culture was induced with 0.1 
mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and grown an additional 6 hours at 
28°C. Cells were harvested by centrifugation and stored at -80°C until needed. IPTG 
induced E. coli BL21(DE3)/pET28-ZN cells were resuspended in buffer A (20 mM 
Imidazole, 0.5M NaCl, 20mM Tris-Cl, pH 7.5) and lysed by sonication. The lysate was 
loaded onto a charged 5-mL Histrap crude column (Amersham Biosciences) and purified 
by FPLC at a flow rate of 5mL/min. The column was washed with buffer A (20 mM 
Imidazole, 0.5 M NaCl, 20 mM Tris-Cl, pH 7.5) and buffer B (500 mM Imidazole, 0.5 M 
NaCl, 20 mM Tris-Cl, pH 7.5) using a step gradient. Fractions containing DnmZ were 
analyzed by SDS-page and buffer was exchanged via a desalting column (HisTrap) using 
buffer C (20 mM Tris-Cl, 1 mM dithiothreitol and 5% glycerol, pH 7.5) and stored at -80 
°C until assayed. 
 
Preparation of TDP-L-epi-vancosamine. 
TDP-L-epivancosamine was biochemically synthesized from Thymidine-5’-
diphospho-α-D-glucose using the general procedures outlined by Chen et al. The 
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following enzymes were used to biochemically transform Thymidine-5’-diphospho-α-D-
glucose to TDP-L-epivancosamine: RfbB from the rhamnose biosynthetic pathway40and, 
EvaA-E from chloroeremomycin biosynthetic pathway. Preparative enzymatic reaction 
progress was followed via HPLC using a series 600 Waters HPLC system with a Waters 
2996 diode array detector. Analytical separations were performed on an Adsorbosphere 
strong anion exchange (SAX) column (5 µm, 4.6 mm  20 mm, Alltech Associates) and a 
linear gradient from 50 to 500 mM NH4HCO2 (pH 3.5) at 1 mL/min for 45 min. 
Preparative HPLC separations were performed using a semipreparative Adsorbosphere 
SAX column (5 μm, 22 mm  250 mm) using a similar protocol, but at 10 mL/min. The pH 
values of the fractions containing TDP chromophores (267 nm) were immediately 
adjusted to ∼7 with 1 M NH4OH, and fractions containing reaction product were pooled, 
lyophilized, and stored at -80 °C until they were assayed. Resuspended compound 
concentrations were determined by measurement of the absorbance at 267 nm using a 
Nanodrop spectrophotometer (Thermo, Inc.) and comparison to a standard curve of 
dTDP. 
 
DnmZ assay with TDP-L-epi-vancosamine. 
Reactions of DnmZ with TDP-L-epivancosamine were performed in a total volume 
of 50 μL containing 30 μM substrate, 30 μM FAD, 1 unit/mL catalase, 1 U/mL 
superoxidedismutase, 0.4 U/mL flavin reductase, and 2.0 mM NADPH. All reactions were 
initiated by addition of 15 μM DnmZ, reactions were quenched with equal volume of 
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acetone, and mixtures stored at -80 °C until they were analyzed by LC-ESI-MS. Control 
assays were performed without DnmZ, FAD, or NADPH. 
 
Derivatization of DnmZ products with hydrazines. 
Upon completion of the DnmZ reaction with TDP-L-epivancosamine, the reaction 
mixture (50 uL) was incubated with the corresponding hydrazine (1 mM) for 2 h at room 
temperature. The mixture was kept at - 80 °C until analyzed by HPLC-MS. The following 
hydrazines were used for the derivatization experiments: phenylhydrazine, 2-
bromophenylhydrazine, and Girard’s reagent (Carboxymethyl)trimethylammonium 
chloride hydrazide; 2-Hydrazino-N,N,N-trimethyl-2-oxo-ethanaminium chloride). 
 
LC-ESI-MS Method for DnmZ assays. 
DnmZ assays were analyzed using Thermo Finnigan (San Jose, CA) TSQ® 
Quantum triple quadrupole mass spectrometer equipped with a standard electrospray 
ionization source outfitted with a 50 μm inside diameter deactivated fused silica 
capillary. Injections of 10 μL were separated using a Hypercarb column (3mm x 50mm, 
Thermo Inc.). Mobile phases were (A) H2O with 50 mM NH4CH3COO and 0.1% (v/v) 
diethylamine and (B) a H2O/acetonitrile mixture (5:95) with 50 mM NH4CH3COO and 
0.1% (v/v) diethylamine. Gradient conditions were as follows: linear gradient from 0 to 
100% B from for  30 min, 100% B from 30 to 40 min, 100% A from 40 to 50 min. The flow 
rate was maintained at 0.2 mL/min. The mass spectrometer was operated in both the 
negative ion and full scan profile modes, and the electrospray needle was maintained at 
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3100 V. The ion transfer tube was operated at -47.50 V and 275 °C. The tube lens 
voltage was set to -46 V. The collision energy for all product ion scans was set at 25%. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Synopsis 
Flavin-dependent monooxygenases are a diverse class of oxidative biocatalysts 
many of which have been extensively studied over the past few decades.1-3 They have 
been shown to catalyze a remarkable wide variety of reactions such as regioselective 
hydroxylations, epioxidations, Bayer-Villiger oxidations and enantioselective 
sulfoxidations. The exquisite specificity and efficiency of these enzymes are often 
unparalleled compared to chemical catalysts.  Recent advances in genome sequence 
data suggested that many more flavin-dependent monooxygenases exist and await 
discovery and characterization. The work presented in this dissertation describes the 
biochemical characterization of a new flavin-dependent monooxygnase, which catalyzes 
the N-oxidation of deoxyaminosugars in vast array of glycosylated natural products. 
The nitrososynthase homologues ORF36 and RubN8 from the everninomicn and 
the rubradirin biosynthetic pathways, respectively, were shown to catalyze the amine to 
nitroso oxidation of the deoxyaminosugar TDP-L-epivancosamine.4-5 Biochemical 
evidence provided in this work, indicates that the nitrososynthase catalysis involves two 
FAD-dependent monooxygenation steps in which the aminosugar is first oxidized to the 
corresponding hydroxylamine, followed by a second iterative N-oxygenation to 
ultimately form the nitrososugar. The nitrososynthase activity is significantly enhanced 
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by the inclusion of an external flavin reductase which generates the reduced flavin 
cofactor required for mediating the oxygenation catalysis. The co-enzyme used for 
reducing equivalents in this interesting flavin-dependen monooxygenation catalysis is 
NADPH. 
Several TDP-aminosugar intermediates in the biosynthetic pathway of TDP-L-
epivancosamine6 were examined as candidate substrates for the N-oxidation by the 
nitrososynthases ORF36 and RubN8. The aminosugar substrates upstream of TDP-L-
epivancosamine underwent only single-oxidation reactions terminating in the 
hydroxylamine oxidation state pointing to the substrate catalytic competence of the 
nitrososynthase enzyme. Performing the nitrososynthase catalysis under 18O2 
demonstrated that the source of oxygen in the oxidation intermediates and products 
stems from molecular oxygen rather than from water, which is consistent with flavin-
dependent monooxygenase catalysis. The X-ray crystal structure of the nitrososynthase 
ORF364 revealed a tetrameric enzyme that shares a fold with acyl-CoA dehydrogenases 
but has an unusually large open active site. 
Surprisingly, the nitrososynthase DnmZ from Streptomyces peucetius was shown 
to mediate a carbon-carbon bond cleavage of the β-hydroxy-nitrososugar produced 
from the N-oxidation of TDP-L-epivancosamine, catalyzed by the same enzyme. This 
retro-aldol activity represents a new and important addition to the functions known for 
flavin-dependent monooxygenases. Furthermore, it explains the biosynthetic origin of 
the once not understood non-sugar acetal moiety in baumycin-like natural products. 
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Future directions 
 
Mechanism of the nitro group formation 
The pathway for the conversion of nitrososugars to their nitrosugar congeners 
remains to be elucidated. To that end, fermentations of S. achromogenes in complete 
darkness produced predominantly protorubradirin, the nitroso congener of rubradirin, 
which reportedly converted to rubradirin (i.e the nitrososugar moiety was oxidized to its 
nitrosugar congener) upon exposure to ambient light.7 This suggested that the oxidation 
to the nitro group is induced photochemically and that the nitrososugar natural product 
congeners are the original biosynthetic metabolites. Seemingly at odds with this, the 
nitrososugar analog of everninomicin was also produced from the fermentation of M. 
carbonacae var. africana along with other derivatives including the nitrosugar analog 
under ambient light.8 Other possibilities for the nitro group formation include oxidation 
via endogenous reactive oxygen species9 or by flavin-dependent monooxygenation 
catalyzed by the nitrososynthase. In our HPLC-MS analysis of the nitrososynthase assay, 
we observed a mass peak corresponding to the TDP-nitrosugar, but it was forming at 
low rates, ambiguous to be counted as an enzymatic conversion.5 Since the TDP-L-
epivancosmine substrate lacks C4 O-methylation and was shown to undergo enzymatic 
carbon-carbon bond cleavage upon the nitrososynthase catalysis, the authentic C4 O-
methylated TDP-aminosugar substrtae (TDP-L-evernosamine) is perhaps more suitable 
for studying the nitro group formation mechanism. We performed preliminary 
nitrososynthase assays with this substrate, which was prepared enzymatically from TDP-
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L-epivancosaime via the C4-methyltransferase RubN7 from the rubradirin pathway 
(Figure V-1), and found that both ORF36 and RubN8 were able to catalyze conversions 
to the nitrososugar (Figure V-II). Additionally, and as expected, there was no hydrate 
observed for this nitrososugar product, consistent with the protection of the C-4 
position. Surprisingly, DnmZ did not oxidize TDP-L-evernosamine suggesting diversity in 
catalytic competence among nitrososynthases. 
 
 
Figure V-1. LC-ESI/MS chromatograms of the preparation of TDP-L-evernosamine via the 
methyltransferase Rubn7 from the rubradirin pathway. 
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Figure V-2. LC-ESI-MS chromatograms of the monooxygenation of TDP-L-evernosamine by ORF36. 
 
A good way to study whether the nitro group formation is catalyzed by a 
nitrososynthase activity is to isolate the C4 O-methylated TDP-nitrososugar and perform 
enzymatic assays of this substrate with the nitrososynthase ORF36.  Analysis by HPLC-
MS using our established methods would show whether this transformation is carried 
out enzymatically. The major challenge that faces this approach is that these TDP-sugars 
are produced in low quantities and are susceptible to hydrolysis of their attached TDP 
moiety. Chemical synthesis of these deoxysugar nucleotides is an alternative route to 
obtain sufficient quantities for enzymatic assays.10 
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Structural studies 
Cocrystallization of the nitrososynthases with FAD or FMN cofactors and/or an 
aminosugar substrate remains an important experiment to perform. Preliminary 
cocrystallization attempts have been so far unsuccessful perhaps due to the complexity 
of substrate and cofactor binding requirements. The nitrososynthase KijD3 from 
Kijaniata actinomadura was successfully cocrystallized with the nucleotide thymidine 
diphosphate phenol (dTDP-phenol).11 While the resulting structure provided only little 
details about the molecular determinates of catalysis, it gave hope for finding 
appropriate cocrystallization conditions for the enzyme-substrate or enzyme-substrate-
cofactor complexes. 
The nitrososynthase co-structures would reveal important amino acid residues 
required for catalysis, while site directed mutagenesis of these residues would validate 
their roles in the monooxygenation mechanism. We performed site directed 
mutagenesis experiments on selected residues chosen based on modeling TDP-L-
epivancosamine and FAD into the active site of ORF36; however, none of the mutations 
abolished the nitrososynthase activity. As discussed in chapter III, the nitrososynthase 
likely undergoes significant conformational adjustment upon substrate binding and 
catalysis thus, identifying the active site residues would require obtaining enzyme-
substrate-FAD co-structures. 
As mentioned above, preliminary experiments suggested that the catalytic 
competence vary among nitrososynthases. For example, unlike ORF36, DnmZ showed 
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no monooxygenase activity with the C4 O-methylated substrate (TDP-L-evernosamine). 
It is intriguing to investigate the structural differences among nitrososynthases that 
allows this interesting selectivity. The recent success in crystallizing the DnmZ enzyme 
by Dr. Jessica Vey’s research group at California State University, Northridge, is a step 
towards the completion of these structural investigations. 
 
Catalytic competence and kinetic studies 
Biochemical characterization of the nitrososynthase enzymes included in this 
work revealed important substrate preference data and set the stage for further 
catalytic competence studies. Our successful enzymatic production of the aminosugar 
substrate TDP-L-evernosamine and the preliminary data of its oxidation by the 
nitrososynthases studied in this work is an effort towards the completion of this goal. 
Michaelis-Menten kinetic measurements12 of the available aminosugar substrates will 
aid in the elucidation of the nirososynthase’s monooxygenation mechanism. Challenges 
that may render kinetic studies problematic via our HPLC-MS methods include the 
availability of the substrates in sufficient quantities, and the susceptibility to hydrolysis 
of their attached TDP moieties. Chemical synthesis of the TDP-sugar substrates10 and 
the use of internal standards are possible solutions for these issues. 
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The interplay between the nitrososynthases and glycosyltransferases 
The remarkable nitrososynthase catalysis described in this work, results in the 
formation of TDP-linked sugar donor substrates of unusual modifications. The 
subsequent sugar cleavage upon the DnmZ activity raises the question as to how this 
cleaved sugar gets attached to its corresponding anthracycline aglycone to ultimately 
form baumycin-like glycosides. One possible scenario for the glycoslation is that the 
resulting cleaved sugar exists in equilibrium with its non-cleaved form which can 
facilitate its glycoslation by the glycosyltransferase DnrH.13 This equilibrium could 
further exist after glycoslation and combined with subsequent chemical or enzymatic 
reduction steps may result in the formation of several baumycin-like compounds.14-15 
Performing glycoslation experiments using the glycosyltransferase DnrH identified in the 
anthracycline biosynthetic pathway in Streptomyces peucetius would test this proposed 
pathway. Some natural product glycosyltransferases require a partner for activity and it 
has been shown that co-expression of the GT with its partner greatly improves the 
solubility of GTs. Gene disruption studies showed that the DnrS glycosyltransferese in 
the daunorubicin biosynthesis requires a protein partner, DnrQ, for its activity.13 These 
considerations should be taken into account when designing the glycoslation 
experiments. The commercial availability of the aglycone substrate daunorubicin is 
advantageously suited for conducting these studies. 
It is also intriguing to determine the preferred substrate for the GT responsible 
for glycoslating of the N-oxidized sugar in everninomicin biosynthesis.  The identity of 
the TDP-sugar donor substrate of glycoslation would reveal important clues into the 
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interplay between the nitrososynthase ORF36 and the subsequent activity of the GT. 
The aglycone substrate can be obtained via a mild hydrolysis of everninomicin described 
by Ganguly, Sarre, and Szmulewicz in U.S. Patent 3,920,629. Our successful production 
of two biogenic sugar donor substrate candidates will aid in the completion of these 
studies. 
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APPENDIX A 
SUPPLEMENTARY FIGURES FROM CHAPTER II 
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Figure A1. SDS-PAGE analysis of the overproduction of RubN8. From left to right, Lane 1: Molecular 
weight markers; Lane 2: Uninduced total protein extract; Lane 3 Induced total protein; Lane 4: Flow-
through of Ni
2+
 column; Lane 5: Pooled fractions from Ni
2+
 column; Lane 6: Desalted fraction. 
 
 
 
 
 
 
Figure A2. DSD-PAGE analysis of the overproduction of RubN8. From left to right, Lane 1: Molecular 
weight markers; Lane 2: Uninduced cell-free extract; Lane 3 Induced cell-free extract; Lane 4: Flow-
through of Ni
2+
 column; Lane 5: Pooled fractions from Ni
2+
 column; Lane 6: Desalted fraction. 
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Figure A3. HPLC/MS analysis of the reduction of TDP-L-epi-vancosamine with TCEP. 
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Figure A4. HPLC/MS analysis of RubN8 catalyzed oxidation reactions with 250 µM TDP-L-epi-
vancosamine and 2 mM NAD(P)H. 
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Figure A5. HPLC/MS analysis of RubN8 catalyzed oxidation reactions with TDP-L-epi-vancosamine and 
400 µM NAD(P)H. 
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Figure A6. MS and Tandem MS of product ions for RubN8 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of the substrate (starting material) TDP-L-epi- vancosamine. 
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Figure A7. MS and Tandem MS of product ions for RubN8 catalyzed reactions.  Shown spectra are MS 
(above) and MS/MS (below) of the hydroxylamine intermediate TDP-L-epi- vancoshydroxylamine. 
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Figure A8. MS and Tandem MS of product ions for RubN8 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of TDP-L-epi-vanconitrose oxidation product (m/z 558). 
 
 
 
166 
 
 
 
 
 
 
 
Figure A9. MS and Tandem MS of product ions for RubN8 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of the hydrated TDP-L-epi-vanconitrose oxidation product (m/z 576). 
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Figure A10. HPLC/MS analysis of ORF36 catalyzed oxidation reactions 250 µM and and 400 µM 
NAD(P)H. 
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Figure A11. MS and Tandem MS of product ions for ORF36 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of the substrate (starting material) TDP-L-epi- vancosamine. 
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Figure A12. MS and Tandem MS of product ions for ORF36 catalyzed reactions.  Shown spectra are MS 
(above) and MS/MS (below) of the hydroxylamine intermediate TDP-L-epi- vancoshydroxylamine. 
 
 
 
 
 
170 
 
 
 
 
 
 
 
 
Figure A13. MS and Tandem MS of product ions for ORF36 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of TDP-L-epi-vanconitrose oxidation product (m/z 558). 
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Figure A14. MS and Tandem MS of product ions for ORF36 catalyzed reactions. Shown spectra are MS 
(above) and MS/MS (below) of the hydrated TDP-L-epi-vanconitrose oxidation product (m/z 576). 
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GTGGCGGCGGATCTTCGCGCGCCGCTCACGCCGGCGGGGCGCACGGTGGTCG
ACCTGCTTGCCGGCGTGATCCCGAGAATCAGTGCGGAGGCCGCCGACCGGGA
CCGCACCGGCACCTTCCCGGTGGAGGCGTTCGAGCAGTTCGCGAAGCTCGGGT
TGATGGGCGCCACCGTTCCCGCCGAGCTGGGCGGCCTGGGGTTGACCCGGCT
GTACGACGTGGCGACCGCGCTGATGCGGCTGGCCGAGGCCGACGCGTCCACC
GCGCTGGCCTGGCACGTGCAGCTCAGCCGGGGCCTCACCCTCACCTACGAGTG
GCAGCACGGCACGCCGCCGGTGCGCGCGATGGCGGAGCGGCTGCTGCGGGC
GATGGCGGAGGGCGAGGCCGCCGTCTGCGGCGCGCTCAAGGACGCCCCCGG
CGTGGTCACCGAGCTGCATTCCGACGGCGCCGGCGGCTGGCTGCTGTCGGGC
CGCAAGGTGCTGGTCAGCATGGCGCCCATCGCGACCCACTTCTTCGTGCACGC
CCAGCGGCGCGACGACGACGGCTCGGTGTTCCTCGCCGTGCCGGTCGTGCAC
CGCGACGCCCCCGGGCTCACGGTGCTGGACAACTGGGACGGCCTGGGAATGC
GTGCCTCGGGGACGCTGGAGGTGGTCTTCGACCGGTGCCCGGTCCGGGCCGA
CGAGCTGCTGGAGCGCGGCCCGGTCGGGGCCCGGCGGGACGCCGTGCTGGC
CGGGCAGACGGTCAGCTCGATCACCATGCTCGGCATCTACGCCGGCATCGCCC
AGGCGGCCCGGGACATCGCGGTCGGTTTCTGCGCGGGGCGCGGCGGCGAGC
CACGGGCCGGTGCCCGGGCGCTGGTCGCCGGGCTGGACACCCGGCTCTACGC
GCTACGCACCACGGTCGGCGCGGCGTTGACCAACGCCGACGCGGCGTCGGTC
GACCTGTCCGGCGACCCGGACGAACGCGGCCGACGGATGATGACCCCGTTCCA
GTACGCGAAGATGACCGTCAACGAGCTGGCCCCGGCGGTGGTGGACGACTGC
CTCAGCCTGGTCGGCGGCCTCGCCTACACGGCCGGGCACCCACTCTCCCGGCT
CTATCGCGACGTGCGGGCCGGCGGGTTCATGCAGCCCTACAGCTACGTGGACG
CCGTCGACTACCTGAGCGGTCAGGCACTTGGACTCGACCGGGACAACGACTAC
ATGAGCGTGCGCGCGCTCCGCTCCCGGACCTCGGCGTAG 
 
Figure A15. Orf36 DNA sequence from Micromonospora carbonacea var africana (NRRL 15099) 
(Genbank locus accession: AX574199). 
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VAADLRAPLTPAGRTVVDLLAGVIPRISAEAADRDRTGTFPVEAFEQFAKLGLMGATVP
AELGGLGLTRLYDVATALMRLAEADASTALAWHVQLSRGLTLTYEWQHGTPPVRAMA
ERLLRAMAEGEAAVCGALKDAPGVVTELHSDGAGGWLLSGRKVLVSMAPIATHFFVHA
QRRDDDGSVFLAVPVVHRDAPGLTVLDNWDGLGMRASGTLEVVFDRCPVRADELLER
GPVGARRDAVLAGQTVSSITMLGIYAGIAQAARDIAVGFCAGRGGEPRAGARALVAGL
DTRLYALRTTVGAALTNADAASVDLSGDPDERGRRMMTPFQYAKMTVNELAPAVVDD
CLSLVGGLAYTAGHPLSRLYRDVRAGGFMQPYSYVDAVDYLSGQALGLDRDNDYMSV
RALRSRTSA* 
 
Figure A16. ORF36 amino acid sequence (does not include His6 tag). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
 
 
ATGGAGACGGAACAGGCCCCCCGGCCGGCCGAGCCACCCGGCGACCTGACCACC
GCCATCACCGCGCCAGGTGAACAGCTGCTGACCCTCCTGGACCGGCACCTGCCCC
GGATACGCGCCCAGGCGGCGCCGAACGACCGGGACAGCACCTTCCCCGCCGCGA
CGTTCCACGGCTTCGCGCGCGACGGCGTGCTGGGCGCGACCGTGCCCGCCGAAC
TGGGAGGGATGGGCGTCAGCCGGCTTCACGACGTGGCGGTCGCGCTTTTGCGGG
TCGCCGAGGCGGACGCCTCGACCGCACTGGCCTTGCACGCCCAGTTCAGCCGGG
GAATCACCCTGACATACGAGTGGCTGCACGGCCCGCCGCCGACCCGGAAACTGG
CCGAGCGGCTGCTGCGCGCGATGGCCCGCGGCGAGGCGGTGATCGGCGGCGCG
GTGAAGGACCACGGACGAGAGACCACCCGGCTGCGCCCCGACGGCTCCGGTGGC
TGGCTGCTGTCCGGACGCAAGACTCTGGTGACGATGGCGCCGATCGCGACGCACT
TCGTCGTCTCCGCCCAGGCGCCGGCCGCCGGGGGAACAACGCTGCTGTACGCCC
CCATCGTGGCACGGGACACCCCGGGGCTCTCCATCGTCGACGGATGGACCGGCC
TGGGCATGCGGGCGTCCGGCACGCTCGACGTGGCGTTCGACGACTGCCCGGTGC
CCGCCGGAAACCTGCTGGCGCGTGGCAGCGTCGGCGCGCACAGCGACGCGGCC
CTCGCCGGGCAGGCGGTCAGCTCCGTCGCCATGCTCGGCATCTACGTCGGCGTC
GCCCAGGCCGCCCGCGACCTCGCGGTGGAGACCATGGCCCGGCGGTCGGCCAC
ACCGCCCGCGGCCTCACGCACCCTGGTCGCCGAGACCGAGGCGCGGCTGTACGC
GCTGCGGGCCACCGCATCGGCTGCGCTCGTCAACGTCGACGAACTGTCGCCACGT
CACGACATGGATCCCGATGAGCGCGGCCGGCGGATGATGACCCCGTTCCAGTGC
GCCAAAGTCATGGTCAACCAACTGGCGGCCGCGGTGGTCGACGACTGCCTCACCG
TGGTGGGCGGGGCCACCTACGCGGCGGAGCACCCGCTGGCCCGGCTGTCCCGG
GACGTGCGGGCCGGCCGGTTCATGCAGCCGTACACGTACGCCGACGGGGTCGAC
TACCTGAGCGCCCAGGCGCTCGGTTTGGAAAGAGACAACAACTACGTGAGCCTGC
GGGCCACCCGGCCGGTGGACAGCCGGTGA 
 
Figure A17. rubN8 DNA sequence from Streptomyces achromogenese var. rubradiris (NRRL3061) 
(Genbank locus accession: AJ871581). 
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METEQAPRPAEPPGDLTTAITAPGEQLLTLLDRHLPRIRAQAAPNDRDSTFPAATFHGF
ARDGVLGATVPAELGGMGVSRLHDVAVALLRVAEADASTALALHAQFSRGITLTYEWL
HGPPPTRKLAERLLRAMARGEAVIGGAVKDHGRETTRLRPDGSGGWLLSGRKTLVTM
APIATHFVVSAQAPAAGGTTLLYAPIVARDTPGLSIVDGWTGLGMRASGTLDVAFDDCP
VPAGNLLARGSVGAHSDAALAGQAVSSVAMLGIYVGVAQAARDLAVETMARRSATPP
AASRTLVAETEARLYALRATASAALVNVDELSPRHDMDPDERGRRMMTPFQCAKVMV
NQLAAAVVDDCLTVVGGATYAAEHPLARLSRDVRAGRFMQPYTYADGVDYLSAQALG
LERDNNYVSLRATRPVDSR* 
 
Figure A18. RubN8 amino acid sequence (Genbank accession: CAI94696) (does not include His6 tag). 
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APPENDIX B 
SUPPLEMENTARY FIGURES FROM CHAPTER III 
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Figure B1. Evolutionary relationships of 13 taxa including nitrososynthases (ORF36 and KijD3), acyl-CoA 
dehydrogenases (ACADS), and flavincontaining monooxygenases.  The evolutionary history was 
inferred using the Neighbor-Joining method. 
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Figure B2.  Active site loops. The loops that form the active site are as follows:  the loops between 3 
and 4 (loop L1; residues 106 – 109), 1 and 2 (loop L2; residues 134-142),3 and 4 (loop L3, residues 
158-164), 4 and 5 (loop L4; residues 178-180), 6 and 7 (loop L5; residues 201-213), 9 and 6 (loop 
L6; residues 248-253), 6’ and 7’ (where the ’ indicates this is from an adjacent monomer; loop L7; 
residues 272-280), 7 and 8 (loop L8; residues 310-317), 8’ and 9’ (loop L9, residues 351-353), 9 
and 10, (loop L10; residues 375-379) and at the C-terminus (loop L11; residues 390-412). (A) A ribbon 
diagram of ORF36 shown with modeled flavin (yellow carbons) and TDP-L-evernosamine (magenta 
carbons) as sticks. Active site loops L3, L5, L7, and L9, are predicted to interact with flavin and are 
colored orange, active site loops L1, L4, L6, L8, and L11 are predicted to interact with substrate and are 
colored purple, and active site loops L2 and L10 are predicted to interact with both substrate and 
cofactor and are colored teal. (B) A ribbon diagram of human short branched-chain acyl Co-A 
dehydrogenase (PDB entry 2JIF) (1), highlighting loops L1 to L11 colored are colored as in (A). (C) A 
ribbon diagram of A. baumannii 4-hydroxyphenylacetate monooxygenase (PDB entry 2JBT) highlighting 
loops L1 to L11 colored as in (A). (D) Stereoview of the ORF36 loop L10 containing a tandem cis-peptide. 
Loop L10 is shown in sticks with teal carbons. The Q376-P377 and P377-Y378 bonds both adopt a cis 
conformation. Modeled flavin and substrate are displayed as in (A).   
 
 
 
 
179 
 
 
Figure B3. Size exclusion chromatogram of ORF36. Size exclusion chromatography of ORF36 on a 
Superdex S-200 column resulted in a single, monodisperse peak. The 10.8 mL elution volume 
corresponds to an approximate molecular weight of 185 kD, which is consistent with the 176 kD 
calculated for a tetramer. 
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Figure B4. Surface representation of the active site clefts of nitrososynthases, acyl-CoA dehydrogenases, 
and flavin-containing monooxygenases are shown colored by B-factor. Active site loops are labeled L1-
L11. Surfaces of each enzyme are shown colored using a rainbow color ramp in which red corresponds 
to the highest B-factor and blue corresponds to the low B-factor. Areas of the surface that form the 
base of the active site cleft are shown in grey. Substrates and co-factors are shown as sticks with atoms 
colored as follows: FAD: carbons, yellow, oxygen, red; nitrogen, blue; phosphate, orange; TDP-L-
evernosamine, dTDP, CoenzymeA persulfide: carbons, magenta; oxygen, red; nitrogen, blue; phosphate, 
orange.  (A) ORF36. Modeled FAD and TDP-L-evernosamine are displayed as sticks.  In this orientation, 
loop L9 is concealed.  The B factor color ramp gradient minimum and maximum values are 70 and 180 
Å
2
, respectively, and for this structure, the Wilson B is 111.2 Å
2
 with an average protein B factor of 
115.3 Å
2
. (B) KijD3 (PDB entry 3M9V) with the dTDP of dTDP-phenol displayed as sticks.  As in (A), loop 
L9 is concealed. The B factor color ramp minimum and maximum values for this panel are 10 and 80 Å
2
, 
and the average protein B value is 27.6 Å
2
.  The Wilson B factor was not reported. (C) Human 
short/branched-chain acyl-CoA dehydrogenase (PDB entry 2JIF). The FAD molecule is concealed by the 
protein surface in this orientation, and coenzymeA persulfide is shown in stick representation. Loops L9 
and 10 are concealed in this orientation. The B factor color ramp gradient has minimum and maximum 
values of 14 and 60 Å
2
, the Wilson B is 25.84 Å
2
 and the average protein B factor is 22.76 Å
2
. (D) A. 
baumannii 4-hydroxyphenylacetate monooxygenase (PDB entry 2JBR). FMN, 4-hydroxyphenylacetate, 
and loops L3, L9 and L10 are concealed in this orientation. The B factor color ramp gradient minimum 
and maximum values are 40 and 90 Å
2
, and the average protein B value is 56.77 Å
2
.  The Wilson B factor 
was not reported.  
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Figure B5.  Location of the FAD and TDP-L-evernosamine molecules modeled within ORF36 active site.  
Chain A of ORF36 is shown colored by domain as in Figure III-2.  Chains B, C and D are colored white, 
black and grey, respectively.  The modeled small molecules (shown as transparent sticks) are colored as 
follows:  FAD, yellow carbons, TDP-L-evernosamine, magenta carbons, oxygen, red; nitrogen, blue; 
sulfur, gold; phosphorus, orange.  (A) The physiologically relevant tetramer, with modeled ligands 
shown at one active site.  (B) A closer view of the labeled ORF36 monomer, shown in stereo.  The 
monomer is shown in the same orientation as in Figure 5b, with the other three chains of the tetramer 
colored as in (A).  Selected secondary structural elements from chain C are labeled in white text. 
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Figure B6.  Stereoview diagrams depicting the active site loops.  Panel (A) shows the ORF36 active site 
loops, displayed as in Figure 7a.  (B) Human short branched-chain acyl Co-A dehydrogenase active site, 
displayed as in Figure B2b.  (C) A. baumannii 4-hydroxyphenylacetate monooxygenase displayed as in 
Figure B2. 
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Figure B7.  Schematic diagram of the active site.  (A) Residues lining the putative FAD binding site are 
diagrammed.  (B) Residues in the vicinity of the modeled FAD cofactor and TDP-L-evernosamine 
substrate are shown.  R’ = the ribityl diphosphonucleotide of the modeled FAD cofactor. 
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Figure B8. Sequence alignment of ORF36 and putative nitrososynthases.  Strictly conserved residues are 
highlighted in black and residues with >70% similarity are boxed.  Residues near the intersection of 
modeled isoalloxazine and TDP-L-evernosamine are boxed in teal and marked with a teal square; 
residues near the isoalloxazine of modeled FAD are boxed in orange and marked with black triangles; 
residues near the nucleotide of modeled FAD are boxed in orange and marked with orange squares; 
and residues near the modeled TDP-L-evernosamine are boxed in purple and marked with purple 
squares.  Secondary structural elements and loops L1-L11 are marked above the alignment and 
highlighted orange (areas involved in flavin binding), purple (areas likely involved in substrate binding) 
or teal (areas located near the intersection of the putative flavin and substrate binding sites).  
Sequences aligned with ORF36 are: KijD3 (UniProtKB ID B3TMR1); TcaB10 from the tetrocarcin A 
biosynthetic pathway of M. chalcea (UniProtKB ID B5L6K4); RubN8 from the rubradirin biosynthetic 
pathway of (UniProtKB ID Q2PC69); B1VRP3, uncharacterized protein from S. griseus; D3CDS4, 
uncharacterized protein from Micromonospora sp. L5.  These proteins were identified by a BLAST 
search of the ORF36 sequence (UniProtKB ID B5APQ9) and all had scores > 450 and E-values of less than 
1x10
-125
.  Sequences were aligned using ClustalW, and the figure was generated using ESPript. 
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Figure B9. Sequence alignment of ORF36, KijD3, selected acyl-coA dehydrogenases, and selected Class D 
flavin monooxygenases.  Loops and residues at the active site are highlighted as in Supplemental Figure 
S4. Of particular interest are the residues involved in the isoalloxazine binding site.  For clarity, select 
divergent portions of individual sequences were truncated and are denoted with red lettering.  
Sequences aligned with ORF36 are: KijD3 (UniProtKB ID B3TMR1); ACAD1, short branched-chain acyl-
coA dehydrogenase (H. sapiens), 2JIF; ACAD2, medium-chain acyl-coA dehydrogenase (S. scrofa), PDB 
entry 3MDE; HpaB1, 4-hydroxyphenylacetate monooxygenase (A. baumannii), PDB entry 2JBT; 
monoox1, 3-hydroxy-9,10-seco-nandrost-1,3,5(10)-triene-9,17-dione hydroxylase (Rhodococcus sp 
Rha1), PDB entry 2RFQ. 
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Figure B10.  Stereoview of electron density for the tandem cis-peptide in L10 of ORF36.  The protein 
chain is depicted as light grey cartoons.  2Fo-Fc electron density is shown in blue for residues 372-389, 
which encompasses the two sequential cis-peptides between Gln376-Pro377 and Pro377-Tyr378.  Those 
residues in loop L10 are shown in stick representation, and the main chain carbon atoms of the cis-
peptides are highlighted in magenta. 
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Figure B11. Stereoview of the ORF36 active site, with the protein shown in putty cartoon 
representation in the same orientation as Figure 7A.  Modeled flavin and substrate are shown as thick 
sticks colored as in Figure 5.  Selected residues within 5.5 Å of the flavin cofactor or L-evernosamine 
that are differ between ORF36 and KijD3 are colored with green carbons, shown in stick representation 
and labeled according to ORF36 numbering. 
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APPENDIX C 
MS AND MS/MS SPECTRA FROM CHAPTER IV 
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Figure C1. MS (above) and MS/MS (below) of the substrate (starting material) TDP-L-epi- vancosamine. 
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Figure C2. MS of the oxime-aldehyde species (m/z 558) and its hydrate (m/z 576) produced from the 
monooxygenation/retro-aldol activity of DnmZ with TDP-L-epi- vancosamine (above), and MS/MS of the 
oxime-aldehyde species (m/z 558) (below). 
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Figure C3. MS/MS of the oxime-aldehyde species (m/z 576) produced from the oxidation/retro-aldol 
activity of  DnmZ withTDP-L-epi- vancosamine. 
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Figure C4.  MS of the phenylhydrazone derivative (m/z 648) produced from the reaction of the 
corresponding oxime-aldehyde with phenylhydrazine. 
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Figure C5. MS of the 2-bromophenylhydrazone derivative (m/z 726, 728) produced from the reaction of 
the corresponding oxime-aldehyde with 2-bromophenylhydrazine (above), and the MS/MS of the 
hydrazone species of m/z 728 (below). 
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Figure C6. MS of the (Carboxymethyl)trimethylammonium (GirT) hydrazone derivative (m/z 673) 
produced from the reaction of the corresponding oxime-aldehyde with GirT hydrazine (above), and the 
MS/MS of the same species (below). Both analyses were performed in the positive mode. 
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Figure C7. MS/MS of the acid hydrolysis fragments of m/z 188 (above), and m/z 215 (below) produced 
from the treatment of the (Carboxymethyl)trimethylammonium (GirT) hydrazone with HCl (1 M). 
 
